Document:

Employment Agreement with John Cavan

 Exhibit 10.5 

EMPLOYMENT AGREEMENT 

This Employment Agreement (“Agreement”) is made as of the 5th day of October, 2010 (the “Effective Date”), between
Aegerion Pharmaceuticals, Inc. a Delaware corporation (the “Company”), and John T. Cavan, an individual who currently resides at 12 E. Elbrook Drive, Allendale, NJ 07401, (the “Executive”) (together the “Parties”).

 WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms and
conditions set forth herein. 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 

1. Position and Duties. The Executive shall serve as the Vice President and Chief Accounting Officer of the Company. In such
capacity, Executive shall have such powers and duties and responsibilities as may from time to time be prescribed by the Company’s Chief Executive Officer and/or the Company’s Board of Directors (the “Board”). The Executive shall
devote his full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may manage his personal investments, engage in religious, charitable or other community activities, as long as such
activities do not pose an actual or apparent conflict of interest and do not interfere with the Executive’s performance of his duties to the Company. Executive represents that he has provided the Company with a comprehensive list of all outside
professional activities with which he is currently involved or reasonably expects to become involved. In the event that, during his employment by the Company, the Executive desires to engage in other outside professional activities, not included on
such list, Executive will first seek written approval from the Board and such approval shall not be unreasonably withheld. 
 2.
Compensation and Related Matters. 
 (a) Base Salary. The Executive’s initial base salary shall be paid at the
rate of $175,000 per year. The Executive’s base salary shall be reviewed annually by the Board or the Compensation Committee of the Board (the “Compensation Committee”). The base salary in effect at any given time is referred
to herein as “Base Salary.” The Base Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices for senior executives. 

(b) Annual Bonus. The Executive shall be eligible to receive an annual cash bonus as determined by the Board or the Compensation
Committee (the “Bonus”). The Bonus shall be based on an annual target and the achievement of performance goals. The Executive’s target shall be 25 percent of his Base Salary. The Executive’s performance goals shall be established
by the Board or the Compensation Committee and the achievement of those goals shall be determined in the sole discretion of the Board or the Compensation Committee. Except as otherwise provided herein, to earn any part of the Bonus, the Executive
must be employed by the Company on December 31 of the applicable bonus year and such Bonus shall be paid to Executive on or before March 15 of the immediately following calendar year. 

 (c) Special Bonus. The Executive shall be eligible to receive a cash bonus equal to
10% of his Base Salary upon acceptance (the “Acceptance Date”) by the U.S. Food and Drug Administration (“FDA”) of a New Drug Application for lomitapide (the “Lomitapide NDA”). Any such bonus will not be earned unless
the Executive is employed by the Company on the Acceptance Date and shall be paid as soon as reasonably practicable following such Acceptance Date but, in any event, no later than March 15 of the immediately following calendar year. 

(d) Equity Grant. The Company shall award the Executive an option (the “Option Award”) to purchase 50,000 shares of the
Company’s common stock, $0.001 par value per share (the “Common Stock”). The Executive shall remain eligible to receive subsequent equity awards from time to time in accordance with the Company’s compensation policies and
procedures then in effect, in any such case, as determined by the Board (or Compensation Committee thereof) acting in its sole discretion. The Option Award shall have an exercise price equal to the fair market value of the Common Stock on the date
of grant (as determined by the Board or Compensation Committee thereof). The Option Award shall vest in equal monthly installments over the four year period commencing as of the date of grant, subject to the terms and conditions set forth in the
Aegerion Pharmaceuticals, Inc. 2006 Stock Option and Grant Plan, as amended, and associated equity award agreements (collectively the “Equity Award Documents”). The term of the Option Award shall be ten (10) years after the date the
Option Award is granted. In connection with a termination of employment within 24 months following a Sale Event (as defined in the Equity Award Documents), 100 percent of Executive’s then outstanding unvested equity shall vest and become fully
exercisable or nonforfeitable as of the date of such termination. 
 (e) Expenses. The Executive shall be entitled to
receive prompt reimbursement for all reasonable expenses incurred by him in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its senior executive officers. 

(f) Other Benefits. The Executive shall be entitled to continue to participate in or receive benefits under the Company’s
employee benefit plans as may be adopted and amended from time to time, subject to the terms and conditions of those employee benefit plans. 

(g) Vacations. The Executive shall be entitled to accrue up to 25 days of paid vacation days in each year, which shall be accrued
ratably, and subject to the Company’s vacation policy in effect, and as may be amended from time to time. 
 3.
Termination. The Executive’s employment hereunder may be terminated without any breach of this Agreement under the following circumstances: 

(a) Death. The Executive’s employment hereunder shall terminate upon his death. 

 

 2 

 (b) Disability. The Company may terminate the Executive’s employment if the
Executive incurs a disability and is unable to perform the essential functions of the Executive’s position with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period. If any question
shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive’s then existing position or positions with or without reasonable accommodation, the Executive may, and
at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the Executive’s guardian has no reasonable objection as to whether the Executive is
so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue. The Executive shall cooperate with any reasonable request of the physician in connection
with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company’s determination of such issue shall be binding on the Executive. Nothing in this Section 3(b) shall be construed
to waive the Executive’s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. §2601 et seq. and the Americans with Disabilities Act, 42 U.S.C. §12101 et
seq. 
 (c) Termination by Company for Cause. The Company may terminate the Executive’s employment at any time
for Cause. For purposes of this Agreement, “Cause” shall mean any of the following by Executive: (i) dishonesty, embezzlement, misappropriation of assets or property of the Company; (ii) gross negligence, willful misconduct,
theft, fraud, or breach of fiduciary duty to the Company; (iii) violation of federal or state securities laws; or (iv) the conviction of a felony, or any crime involving moral turpitude, including a plea of guilty or nolo contendere;
(v) a material breach of any material provision of this Agreement; or (vi) a material breach of any of the Company’s written policies relating to conduct or ethics. 

(d) Termination by the Company Without Cause. The Company may terminate the Executive’s employment at any time without Cause.
Any termination by the Company of the Executive’s employment under this Agreement which does not constitute a termination for Cause under Section 3(c) and does not result from the death or disability of the Executive under
Section 3(a) or 3(b) shall be deemed a termination without Cause. 
 (e) Termination by the Executive. The Executive
may terminate his employment hereunder at any time for any reason, including but not limited to Good Reason. For purposes of this Agreement, “Good Reason” shall mean that the Executive has complied with the “Good Reason Process”
(hereinafter defined) following the occurrence of any of the following events: (i) a material diminution in the Executive’s responsibilities, authority or duties; (ii) a material diminution in the Executive’s Base Salary;
(iii) a material change without the Executive’s consent of the principal location of the Executive’s offices provided that such consent may not be unreasonably withheld, or (iv) the material breach of a material provision of this
Agreement by the Company. “Good Reason Process” shall mean that (i) the Executive reasonably determines in good faith that a “Good Reason” condition has occurred; (ii) the Executive notifies the Company in writing of
the first occurrence of the Good Reason condition within 30 days of the first occurrence of such condition; (iii) the Executive cooperates in good faith with the Company’s efforts, for a period not less than 30 days following such notice
(the “Cure Period”), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason 
  

 3 

 
condition continues to exist; and (v) the Executive terminates his employment within 30 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure
Period, Good Reason shall be deemed not to have occurred. 
 (f) Notice of Termination. Except for termination as
specified in Section 3(a), any termination of the Executive’s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this
Agreement, a “Notice of Termination” shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon. 

(g) Date of Termination. “Date of Termination” shall mean: (i) if the Executive’s employment is terminated by
his death, the date of his death; (ii) if the Executive’s employment is terminated on account of disability under Section 3(b) or by the Company with Cause under Section 3(c) or without Cause under Section 3(d) on the date
the Notice of Termination is given; (iii) if the Executive’s employment is terminated by the Executive under Section 3(e) without Good Reason, 30 days after the date on which a Notice of Termination is given, and (iv) if the
Executive’s employment is terminated by the Executive under Section 3(e) with Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, in the event that the Executive
gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement. 

4. Compensation Upon Termination. 

(a) Termination Generally. If the Executive’s employment with the Company is terminated for any reason, the Company shall pay
or provide to the Executive (or to his authorized representative or estate) any earned but unpaid salary and bonus, if any, unpaid expense reimbursements, accrued but unused vacation and any vested benefits the Executive may have under any employee
benefit plan of the Company (the “Accrued Benefit”) on or before the time required by law but in no event more than 30 days after the Executive’s Date of Termination. 

(b) Termination by the Company Without Cause or by the Executive with Good Reason. If the Executive’s employment is
terminated by the Company without Cause as provided in Section 3(d), or the Executive terminates his employment for Good Reason as provided in Section 3(d), then the Company shall, through the Date of Termination, pay the Executive his
Accrued Benefit. In addition, subject to the Executive providing the Company with a fully effective separation agreement that includes a general release of claims in a form and manner reasonably satisfactory to the Company (the “Release”)
within the 35-day period following the Date of Termination, Executive shall be entitled to the following payments and benefits (collectively the “Severance Benefits”): 

(i) the Company shall pay the Executive severance pay in the form of continuation of Executive’s Base Salary for six
(6) months in accordance with the Company’s payroll practice, beginning on the Company’s first regular payroll date that occurs 35 days after the Date of Termination. Solely for purposes of Section 409A of the Internal
Revenue Code of 1986, as amended (the “Code”), each salary continuation payment is considered a separate payment; 
  

 4 

 (ii) subject to the Executive’s timely election of COBRA and copayment
of premium amounts at the active employees’ rate, the Executive may continue to participate in the Company’s group health and dental program until the earlier of (i) six (6) months from the Date of Termination, and (ii) the
date the Executive becomes re-employed with benefits substantially comparable to the benefits provided under the corresponding Company plan; 

(iii) notwithstanding anything to the contrary in any Equity Award Documents, in the event that the Executive’s
employment is terminated by the Company without Cause or by the Executive with Good Reason and the Date of Termination occurs within twelve (12) months of the Effective Date (a) 25% of the Executive’s then outstanding unvested equity
awards shall vest and become fully exercisable or nonforfeitable as of the Date of Termination, and (b) Executive shall have ninety (90) days from the Date of Termination to exercise vested equity awards; and 

(iv) in the event that the Executive’s employment is terminated by the Company without Cause or by the Executive with
Good Reason and the Date of Termination occurs within twenty four (24) months following Sale Event (as defined in the Equity Award Documents), the Bonus payment the Executive earned pursuant to Section 2(b) of this Agreement for the bonus
period that immediately preceded the Date of Termination. 
 Notwithstanding the foregoing, the Severance Benefit set forth in
Section 4(b)(i) shall be reduced dollar for dollar by any compensation Executive receives from another employer during the period between the Date of Termination and the last day of the severance period (the “Severance Benefits
Period”) if the Executive becomes re-employed during the Severance Benefits Period. The Executive agrees to give prompt notice of any employment during the Severance Benefits Period and shall respond promptly to any reasonable inquiries
concerning his professional activities. If the Company makes any overpayments of Severance Benefits, Executive shall promptly return any such overpayments to the Company and/or hereby authorizes deductions from future Severance Benefit amounts. The
foregoing shall not create any obligation on the part of the Executive to seek re-employment after the Date of Termination. 

5. Section 409A. 

(a) Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive’s separation from service within the
meaning of Section 409A of the Code, the Company determines that the Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive
becomes entitled to under this Agreement on account of the Executive’s separation from service would be considered deferred compensation subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result
of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after the

  

 5 

 
Executive’s separation from service, or (B) the Executive’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a
catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule. 

(b) All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or
incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following
the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any
other taxable year. Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. 

(c) To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation”
under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive’s termination of employment, then such payments or benefits shall be payable only upon the Executive’s “separation from
service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h). 

(d) The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any
provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. The parties agree that this
Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder
without additional cost to either party. 
 (e) The Company makes no representation or warranty and shall have no liability to
the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. 

6. Confidential Information, Noncompetition and Cooperation; Nondisparagement. 

(a) Restrictive Covenant. As a condition of Executive’s employment and as a material term of this Agreement, the Executive
agrees to comply with the Employee Confidentiality, Assignment and Noncompetition Agreement attached hereto as Exhibit 1, the terms of which are hereby incorporated by reference into Section 6 of this Agreement. 

(b) Litigation and Regulatory Cooperation. During and after the Executive’s employment, the Executive shall cooperate fully
with the Company in the defense or prosecution 
  

 6 

 
of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while the Executive was
employed by the Company, provided, that the Executive will not have an obligation under this paragraph with respect to any Claim in which the Executive has filed directly against the Company or related persons or entities. The Executive’s full
cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During
and after the Executive’s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to
events or occurrences that transpired while the Executive was employed by the Company, provided the Executive will not have any obligation under this paragraph with respect to any claim in which the Executive has filed directly against the Company
or related persons or entities. The Company shall reimburse the Executive for any reasonable out-of-pocket expenses incurred in connection with the Executive’s performance of obligations pursuant to this Section 6(b). 

(c) Injunction; Termination of Post-employment Payments. The Executive agrees that it would be difficult to measure any damages
caused to the Company which might result from any breach by the Executive of the promises set forth in this Section 6, including without limitation, any provision of Exhibit 1, and that in any event money damages would be an inadequate remedy
for any such breach. Accordingly, the Executive agrees that if the Executive breaches, or proposes to breach, any portion of this Agreement, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other
appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company. In addition to the foregoing, if the Executive breaches any of the provisions contained in Section 6 of this Agreement, the
Company shall, in addition to all other rights and remedies, have the right to cease paying any payments or benefits pursuant to Section 4(b)) of this Agreement. Any such termination of payment or benefits shall have no effect on the Release or
any of Executive’s post-employment obligations to the Company. 
 7. Indemnification. The Company and the Executive
shall enter into an indemnification agreement in a form approved by the Board for the Company’s senior executives. 
 8.
Consent to Jurisdiction. To the extent that any court action is initiated to enforce this Agreement, the parties hereby consent to the jurisdiction of the state and federal courts of the Commonwealth of Massachusetts. Accordingly, with
respect to any such court action, the Executive (a) submits to the personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or
otherwise) with respect to personal jurisdiction or service of process. 
 9. Integration. This Agreement, along with
Exhibit 1, the Equity Award Documents and any other option agreements between the Company and the Executive, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between
the parties concerning such subject matter herein, including that offer letter between the Company and the Executive dated April 20, 2006. 
  

 7 

 10. Withholding. All payments made by the Company to the Executive under this
Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law. Nothing herein shall be construed to obligate the Company to design or implement any compensation arrangement in a way that minimizes tax
consequences for Executive. 
 11. Successor to the Executive. This Agreement shall inure to the benefit of and be
enforceable by the Executive’s personal representatives, executors, administrators, heirs, distributees, devisees and legatees. In the event of the Executive’s death after his termination of employment but prior to the completion by the
Company of all payments due him under this Agreement, the Company shall continue such payments to the Executive’s beneficiary designated in writing to the Company prior to his death (or to his estate, if the Executive fails to make such
designation). 
 12. Enforceability. If any portion or provision of this Agreement (including, without limitation, any
portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in
circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. 

13. Survival. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the
Executive’s employment to the extent necessary to effectuate the terms contained herein. 
 14. Waiver. No waiver of
any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this
Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. 

15. Notices. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in
writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with
the Company or, in the case of the Company, at its main offices, attention of the Board. 
 16. Amendment. This Agreement
may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company. 

17. Governing Law. This is a Massachusetts contract and shall be construed under and be governed in all respects by the laws of
the Commonwealth of Massachusetts without giving effect to the conflict of laws principles of such state. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted
and applied by the United States Court of Appeals for the First Circuit. 
  

 8 

 18. Counterparts. This Agreement may be executed in any number of counterparts, each
of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. 

19. Successor to Company. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation
or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no succession had taken place. Failure
of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession shall be a material breach of this Agreement. 

20. Gender Neutral. Wherever used herein, a pronoun in the masculine gender shall be considered as including the feminine gender
unless the context clearly indicates otherwise. 
 IN WITNESS WHEREOF, the parties have executed this Agreement effective on the
date and year first above written. 
  

			
	AEGERION PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Marc D. Beer

	Its:	 	 Chief Executive Officer

	
	EXECUTIVE
	
	 /s/ John T. Cavan

	John T. Cavan
	
	 October 5, 2010

	Date

  

 9 

 Exhibit 1 

AEGERION PHARMACEUTICALS, INC. 

Employee Confidentiality, Assignment and Noncompetition Agreement 

In consideration and as a condition of my employment or continued employment by Aegerion Pharmaceuticals, Inc. (the “Company”),
I agree as follows: 
 1. Proprietary Information. I agree that all information, whether or not in writing,
concerning the Company’s business, technology, business relationships or financial affairs which the Company has not released to the general public (collectively, “Proprietary Information”) is and will be the exclusive property of the
Company. By way of illustration, Proprietary Information may include information or material which has not been made generally available to the public, such as: (a) corporate information, including plans, strategies, methods, policies,
resolutions, negotiations or litigation; (b) marketing information, including strategies, methods, customer identities or other information about customers, prospect identities or other information about prospects, or market analyses or
projections; (c) financial information, including cost and performance data, debt arrangements, equity structure, investors and holdings, purchasing and sales data and price lists; and (d) operational and technological
information, including plans, specifications, manuals, forms, templates, software, designs, methods, procedures, formulas, discoveries, inventions, improvements, concepts and ideas; and (e) personnel information, including personnel
lists, reporting or organizational structure, resumes, personnel data, compensation structure, performance evaluations and termination arrangements or documents. Proprietary Information also includes information received in confidence by the Company
from its customers or suppliers or other third parties. 
 2. Recognition of Company’s Rights. I will not, at
any time, without the Company’s prior written permission, either during or after my employment, disclose any Proprietary Information to anyone outside of the Company, or use or permit to be used any Proprietary Information for any purpose other
than the performance of my duties as an employee of the Company. I will cooperate with the Company and use my best efforts to prevent the unauthorized disclosure of all Proprietary Information. I will deliver to the Company all copies of Proprietary
Information in my possession or control upon the earlier of a request by the Company or termination of my employment. 
 3.
Rights of Others. I understand that the Company is now and may hereafter be subject to non-disclosure or confidentiality agreements with third persons which require the Company to protect or refrain from use of proprietary information.
I agree to be bound by the terms of such agreements in the event I have access to such proprietary information. 
 4.
Commitment to Company; Avoidance of Conflict of Interest. While an employee of the Company, I will devote my full-time efforts to the Company’s business and I will not engage in any other business activity that conflicts with my
duties to the Company. I will advise the Chief Executive Officer of the Company at such time as any activity of either the Company or another business presents me with a conflict of interest or the appearance of a conflict of interest as an employee
of the Company. I will take whatever action is requested of me by the Company to resolve any conflict or appearance of conflict which it finds to exist. 

5. Developments. I will make full and prompt disclosure to the Company of all inventions, discoveries, designs,
developments, methods, modifications, improvements, processes, algorithms, databases, computer programs, formulae, techniques, trade secrets, graphics or images, and audio or visual works and other works of authorship, whether or not patentable or
copyrightable, that are created, made, conceived or reduced to practice by me (alone or jointly with others) or under my direction during the period of my employment (collectively, the “Developments”). I acknowledge that all work performed
by me is on a “work for hire” basis, and I hereby do assign and transfer and, to the extent any such assignment cannot be made at present, will assign and transfer, to the Company and its successors and assigns all my right, title and
interest in all Developments that (a) relate to the business of the Company or any customer of the Company or any of the products or services being researched, developed, manufactured or sold by the Company or which may be used with such
products or services; or (b) result from tasks assigned to me by the Company; or (c) result from the use of premises or personal property (whether tangible or intangible) owned, leased or contracted for by the Company
(“Company-Related Developments”), and all related patents, patent applications, trademarks and trademark applications, copyrights and copyright applications, and other intellectual property rights in all countries and territories worldwide
and under any international conventions (“Intellectual Property Rights”). 
 To preclude any possible uncertainty, I have set forth on
Exhibit A attached hereto a complete list of Developments that I have, alone or jointly with others, conceived, developed or reduced to practice prior to the commencement of my employment with the Company that I consider to be my property or
the property of third parties and that I wish to have excluded from the scope of this Agreement (“Prior Inventions”). If disclosure of any such Prior Invention would cause me to violate any prior confidentiality agreement, I understand
that I am not to list such Prior Inventions in Exhibit A but am only to disclose a cursory name for each such invention, a listing of the party(ies) to whom it belongs and the fact that full disclosure as to such inventions has not been made
for that reason. I have also listed on Exhibit A all patents and patent applications in which I am named as an inventor, other than those which have been assigned to the Company (“Other Patent Rights”). If no such disclosure is

 
attached, I represent that there are no Prior Inventions or Other Patent Rights. If, in the course of my employment with the Company, I incorporate a Prior Invention into a Company product,
process or machine or other work done for the Company, I hereby grant to the Company a nonexclusive, royalty-free, paid-up, irrevocable, worldwide license (with the full right to sublicense) to make, have made, modify, use, sell, offer for sale and
import such Prior Invention. Notwithstanding the foregoing, I will not incorporate, or permit to be incorporated, Prior Inventions in any Company-Related Development without the Company’s prior written consent. 

This Agreement does not obligate me to assign to the Company any Development which, in the sole judgment of the Company, reasonably exercised, is
developed entirely on my own time and does not relate to the business efforts or research and development efforts in which, during the period of my employment, the Company actually is engaged or reasonably would be engaged, and does not result from
the use of premises or equipment owned or leased by the Company. However, I will also promptly disclose to the Company any such Developments for the purpose of determining whether they qualify for such exclusion. I understand that to the extent this
Agreement is required to be construed in accordance with the laws of any state which precludes a requirement in an employee agreement to assign certain classes of inventions made by an employee, this paragraph 5 will be interpreted not to apply to
any invention which a court rules and/or the Company agrees falls within such classes. I also hereby waive all claims to any moral rights or other special rights which I may have or accrue in any Company-Related Developments. 

6. Documents and Other Materials. I will keep and maintain adequate and current records of all Proprietary Information and
Company-Related Developments developed by me during my employment, which records will be available to and remain the sole property of the Company at all times. 

All files, letters, notes, memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification
sheets, or other written, photographic or other tangible material containing Proprietary Information, whether created by me or others, which come into my custody or possession, are the exclusive property of the Company to be used by me only in the
performance of my duties for the Company. Any property situated on the Company’s premises and owned by the Company, including without limitation computers, disks and other storage media, filing cabinets or other work areas, is subject to
inspection by the Company at any time with or without notice. In the event of the termination of my employment for any reason, I will deliver to the Company all files, letters, notes, memoranda, reports, records, data, sketches, drawings, notebooks,
layouts, charts, quotations and proposals, specification sheets, or other written, photographic or other tangible material containing Proprietary Information, and other materials of any nature pertaining to the Proprietary Information of the Company
and to my work, and will not take or keep in my possession any of the foregoing or any copies. 
 7. Enforcement of
Intellectual Property Rights. I will cooperate fully with the Company, both during and after my employment with the Company, with respect to the procurement, maintenance and enforcement of Intellectual Property Rights in Company-Related
Developments. I will sign, both during and after the term of this Agreement, all papers, including without limitation copyright applications, patent applications, declarations, oaths, assignments of priority rights, and powers of attorney, which the
Company may deem necessary or desirable in order to protect its rights and interests in any Company-Related Development. If the Company is unable, after reasonable effort, to secure my signature on any such papers, I hereby irrevocably designate and
appoint each officer of the Company as my agent and attorney-in-fact to execute any such papers on my behalf, and to take any and all actions as the Company may deem necessary or desirable in order to protect its rights and interests in any
Company-Related Development. 
 8. Non-Competition and Non-Solicitation. In order to protect the Company’s
Proprietary Information and good will, during my employment and for a period of six (6) months following the termination of my employment for any reason (the “Restricted Period”), I will not directly or indirectly, whether as owner,
partner, shareholder, director, manager, consultant, agent, employee, co-venturer or otherwise, engage, participate or invest in any business activity anywhere in the world that develops, manufactures or markets any products, or performs any
services, that are competitive with the products or services of the Company, or products or services that the Company or its affiliates, has under development or that are the subject of active planning at any time during my employment; provided that
this shall not prohibit any possible investment in publicly traded stock of a company representing less than one percent of the stock of such company. In addition, during the Restricted Period, I will not, directly or indirectly, in any manner,
other than for the benefit of the Company, (a) call upon, solicit, divert, take away, accept or conduct any business from or with any of the customers or prospective customers of the Company or any of its suppliers, and/or (b) solicit,
entice, attempt to persuade any other employee or consultant of the Company to leave the Company for any reason. I acknowledge and agree that if I violate any of the provisions of this paragraph 8, the running of the Restricted Period will be
extended by the time during which I engage in such violation(s). 
 9. Government Contracts. I acknowledge that
the Company may have from time to time agreements with other persons or with the United States Government or its agencies which impose obligations or restrictions on the Company regarding inventions made during the course of work under such
agreements or regarding the confidential nature of such work. I agree to comply with any such obligations or restrictions upon the direction of the Company. In addition to the rights assigned under paragraph 5, I also assign to the Company (or any
of its nominees) all rights which I have or acquired in any Developments, full title to which is required to be in the United States under any contract between the Company and the United States or any of its agencies. 

 

 2 

 10. Prior Agreements. I hereby represent that, except as I have fully
disclosed previously in writing to the Company, I am not bound by the terms of any agreement with any previous employer or other party to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of
my employment with the Company or to refrain from competing, directly or indirectly, with the business of such previous employer or any other party. I further represent that my performance of all the terms of this Agreement as an employee of the
Company does not and will not breach any agreement to keep in confidence proprietary information, knowledge or data acquired by me in confidence or in trust prior to my employment with the Company. I will not disclose to the Company or induce the
Company to use any confidential or proprietary information or material belonging to any previous employer or others. 
 11.
Remedies Upon Breach. I understand that the restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company and I consider them to be reasonable for such purpose. Any breach of this
Agreement is likely to cause the Company substantial and irrevocable damage and therefore, in the event of such breach, the Company, in addition to such other remedies which may be available, will be entitled to seek specific performance and other
injunctive relief, without the posting of a bond. If I violate this Agreement, in addition to all other remedies available to the Company at law, in equity, and under contract, I agree that I am obligated to pay all the Company’s costs of
enforcement of this Agreement, including attorneys’ fees and expenses. 
 12. Use of Voice, Image and Likeness.
During the period of my employment, I give the Company permission to use any and all of my voice, image and likeness, with or without using my name, in connection with the products and/or services of the Company, for the purposes of advertising
and promoting such products and/or services and/or the Company, and/or for other purposes deemed appropriate by the Company in its reasonable discretion, except to the extent expressly prohibited by law. 

13. Publications and Public Statements. I will obtain the Company’s written approval before publishing or submitting
for publication any material that relates to my work at the Company and/or incorporates any Proprietary Information. 
 14.
No Employment Obligation. I understand that this Agreement does not create an obligation on the Company or any other person to continue my employment. I acknowledge that, unless otherwise agreed in a formal written employment agreement
signed on behalf of the Company by an authorized officer, my employment with the Company is at will and therefore may be terminated by the Company or me at any time and for any reason, with or without cause. 

15. Survival and Assignment by the Company. I understand that my obligations under this Agreement will continue in
accordance with its express terms regardless of any changes in my title, position, duties, salary, compensation or benefits or other terms and conditions of employment. I further understand that my obligations under this Agreement will continue
following the termination of my employment regardless of the manner of such termination and will be binding upon my heirs, executors and administrators. The Company will have the right to assign this Agreement to its affiliates, successors and
assigns. I expressly consent to be bound by the provisions of this Agreement for the benefit of the Company or any parent, subsidiary or affiliate to whose employ I may be transferred without the necessity that this Agreement be resigned at the time
of such transfer. 
 16. Updating Information to the Company; Disclosure to Future Employers. For six
(6) months following termination of my employment, I will (i) notify the Company of any change in my address and of each subsequent employment or business activity, including the name and address of my employer or other post-Company
employment plans and the nature of my activities, and (ii) provide a copy of this Agreement to any prospective employer, partner or coventurer prior to entering into an employment, partnership or other business relationship with such person or
entity. 
 17. Severability. In case any provisions (or portions thereof) contained in this Agreement shall, for
any reason, be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect the other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or
unenforceable provision had never been contained herein. If, moreover, any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it
shall be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it shall then appear. 

18. Interpretation. This Agreement will be deemed to be made and entered into in the Commonwealth of Massachusetts, and
will in all respects be interpreted, enforced and governed under the laws of the Commonwealth of Massachusetts. I hereby agree to consent to personal jurisdiction of the state and federal courts situated within Suffolk County, Massachusetts for
purposes of enforcing this Agreement, and waive any objection that I might have to personal jurisdiction or venue in those courts. 
  

 3 

 I UNDERSTAND THAT THIS AGREEMENT AFFECTS IMPORTANT RIGHTS. BY SIGNING BELOW, I CERTIFY THAT I HAVE READ
IT CAREFULLY AND AM SATISFIED THAT I UNDERSTAND IT COMPLETELY. 
 IN WITNESS WHEREOF, the undersigned has executed this
agreement as a sealed instrument as of the date set forth below. 
  

			
	Signed:	 	 /s/ John T. Cavan

	 	 	 (Employee’s full name)

	
	Type or print name: John T. Cavan

					
			
	Date:	 	 10/5/10
	 	 

 EXHIBIT A 

 

			
	To:	  	Aegerion Pharmaceuticals, Inc. ,
		
	From:	  	  

		
	Date:	  	  

		
	SUBJECT:	  	            Prior Inventions

The following is a complete list of all inventions or improvements relevant to the subject matter of my employment by the Company that
have been made or conceived or first reduced to practice by me alone or jointly with others prior to my engagement by the Company: 
  

	
	No inventions or improvements
	
	See below:
	
	  

	
	  

	
	  

	
	Additional sheets attached

 The following is
a list of all patents and patent applications in which I have been named as an inventor: 
  

	
	None
	
	See below:License Agreement with Bayer Healthcare AG

 Exhibit 10.7 

EXECUTION COPY 
 [CONFIDENTIAL
TREATMENT REQUESTED] /*/ INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED. 
 LICENSE AGREEMENT 

This License Agreement (this “Agreement”), dated as of May 31, 2006 (the “Effective Date”), is made by
and between Bayer HealthCare AG, a German corporation (“Bayer”), and Aegerion Pharmaceuticals, Inc., a Delaware corporation (“Aegerion”). Bayer and Aegerion are sometimes hereinafter referred to each as a “Party” and
collectively as the “Parties.” 
 WHEREAS, Bayer has been engaged in the development of implitapide as an inhibitor of
microsomal triglyceride transfer protein (“MTP”), and owns and otherwise controls certain patent rights and know-how with respect thereto; 

WHEREAS, Aegerion desires to acquire exclusive rights under the Bayer Patent Rights and Bayer Know-How (as defined below) in order to
continue the development thereof and products based thereupon; and 
 WHEREAS, the Parties desire to enter into an agreement
pursuant to which Bayer will grant an exclusive license to Aegerion under the Bayer Patent Rights and Bayer Know-How for Aegerion to develop and commercialize Licensed Compounds and Licensed Products (as defined below). 

NOW, THEREFORE, the Parties hereby agree as follows: 

Section 1. Definitions. 

For the purpose of this Agreement, the following words and phrases shall have the meanings set forth below: 

1.1 “Affiliate” of an entity means any other entity which (directly or indirectly) is controlled by, controls or is under
common control with such entity. For the purposes of this definition, the term “control” (including, with correlative meanings, the terms “controlled by” and “under common control with”) as used with respect
to an entity means (i) in the case of a corporate entity, direct or indirect ownership of voting securities entitled to cast at least fifty percent (50%) of the votes in the election of directors or (ii) in the case of a non-corporate
entity, direct or indirect ownership of at least fifty percent 50%) of the equity interests with the power to direct the management and policies of such entity, provided that if local law restricts foreign ownership, control shall be
established by direct or indirect ownership of the maximum ownership percentage that may, under such local law, be owned by foreign interests. 

1.2 “Bayer Know-How” means all Technology, now existing or hereafter arising during the time the license grant set forth in
Section 2.1 is in effect, owned or otherwise Controlled by Bayer or any of its Affiliates, that is related to the Bayer Patent Rights or that is reasonably necessary or useful for the manufacture, use, sale, offer for sale, importation,
research, development or commercialization or other exploitation of any Licensed Compounds or Licensed Products or Improvements. Exhibit A attached hereto lists specific Bayer Know-How. 

 LICENSE AGREEMENT 

 

 1.3 “Bayer Patent Rights” means: 

(a) the patents and patent applications listed in Exhibit B-1 attached hereto, plus (a) all divisionals,
continuations, continuations-in-part thereof or any other patent application claiming priority directly or indirectly to (i) any of the patents or patent applications identified on Exhibit B-1 or (ii) any patent or patent
application from which the patents or patent applications identified on Exhibit B-1 claim direct or indirect priority, and (b) all patents issuing on any of the foregoing; and 

(b) all other patents and patent applications owned or otherwise Controlled by Bayer or any of its Affiliates during the
time the license grant set forth in Section 2.1 is in effect that (i) claim any Improvements or their manufacture or use, or (ii) that are reasonably necessary for the manufacture, use sale, offer for sale, importation, research,
development or commercialization or other exploitation of any Licensed Compounds or Licensed Products (the patents and patent applications of this clause (b), collectively “Bayer Improvement Patents”), which Bayer Improvement
Patents the Parties shall list on Exhibit B-2 attached hereto during the term of this Agreement as provided for in Section 6.1, together with all registrations, reissues, re examinations, renewals, supplemental protection
certificates and extensions of any of the foregoing, and all foreign counterparts thereof. 
 1.4 “Combination
Product” means a Licensed Product that includes at least one additional active ingredient other than Licensed Compound. Drug delivery vehicles, adjuvants, and excipients shall not be deemed to be “active ingredients”, except in the
case where such delivery vehicle, adjuvant, or excipient is recognized as an active ingredient in accordance with 21 C.F.R. 210.3(b)(7). 

1.5 “Commercially Reasonable Efforts” means, with respect to Licensed Products, the carrying out of development and
commercialization activities in a sustained manner using good faith commercially reasonable and diligent efforts, using the efforts that a company within the pharmaceutical industry and similarly situated to Aegerion would reasonably devote to a
product of similar market potential or profit potential resulting from its own research efforts, based on conditions then prevailing and taking into account, without limitation, issues of safety and efficacy, product profile, the proprietary
position, the then current competitive environment for such product and the likely timing of such product’s entry into the market, the regulatory environment and status of such product, and other relevant scientific, technical and commercial
factors. 
 1.6 “Confidential Information” means all Technology, chemical or biological materials, marketing plans,
strategies and customer lists, and other information that are disclosed or provided by such Party or its Affiliates to the other Party or its Affiliates, regardless of whether any of the foregoing are marked “confidential”
or “proprietary” or communicated to the other by the disclosing Party or its Affiliates in oral, written, graphic, or electronic form. 

1.7 “Confidentiality Agreement” means that certain Mutual Nondisclosure Agreement, dated October 5, 2005, by and between
the Parties. 
 1.8 “Controlled” or “Controls”, when used in reference to patent or other intellectual
property rights or Technology, means the legal authority or right of a person or entity to grant a license or sublicense of intellectual property rights to another person or entity, or to otherwise disclose or provide Technology to such other person
or entity, without breaching the terms of any agreement with a different person or entity. 
 1.9 “FDA” means the
United States Food and Drug Administration or any successor agency thereto. 
 1.10 “First Commercial Sale” means,
with respect to any Licensed Product on a country-by-country basis, the first sale for use by the general public of such Licensed Product in such country after marketing approval of such Licensed Product has been granted, or marketing and sale of
such Licensed Product is otherwise permitted, by the applicable regulatory authority of such country. 
  

 2 

 LICENSE AGREEMENT 

 

 1.11 “Improvements” means all Technology that amount to improvements to any of
the inventions claimed by the Bayer Patent Rights or to the Bayer Know-How made, developed, conceived, owner or otherwise Controlled by Bayer or any of its Affiliates after the date hereof, whether or not patentable or patented. 

1.12 “Licensed Compound” means (a) the compound known as Bay 13-9952 and identified as “implitapide,” and
(b) any metabolic precursors, prodrugs, isomers (chiral and otherwise), metabolites, hydrates, anhydrides, solvates, salt forms, free acids or bases, esters, amides, ethers, complexes, conjugates or polymorphs of any compounds covered by the
foregoing clause (a) or this clause (b). 
 1.13 “Licensed Product” means any pharmaceutical product
containing a Licensed Compound (alone or with other active ingredients), in all forms, presentations, formulations and dosage forms. For clarification, Licensed Product shall include any Combination Product. 

1.14 “NDA” means a New Drug Application filed with the FDA required for marketing approval for the applicable Licensed Product
in the United States. 
 1.15 “Net Sales” means, with respect to any Licensed Product, the amount received by Aegerion
and its Affiliates and Sublicensees for bona fide sales of such Licensed Product to a Third Party (other than Sublicensees and Aegerion’s Afffiliates but including distributors for resale), less: 

(a) discounts (including cash, quantity and patient program discounts), retroactive price reductions, charge-back payments
and rebates granted to managed health care organizations or to federal, state and local governments, their agencies, and purchasers and reimbursers or to trade customers; 

(b) credits or allowances actually granted upon claims, damaged goods, rejections or returns of such Licensed Product,
including such Licensed Product returned in connection with recalls or withdrawals; 
 (c) freight out, postage,
shipping and insurance charges for delivery of such Licensed Product; and 
 (d) taxes or duties levied on,
absorbed or otherwise imposed on the sale of such Licensed Product, including value-added taxes, or other governmental charges otherwise imposed upon the billed amount, as adjusted for rebates and refunds, to the extent not paid by the Third Party.

 Net Sales shall not include any payments among Aegerion, its Affiliates and Sublicensees. Net Sales shall be determined in
accordance with generally accepted accounting principles, consistently applied. Net Sales for any Combination Product shall be calculated on a country-by-country basis by multiplying actual Net Sales of such Combination Product by the fraction A/B,
where A is the weighted average price paid for the Licensed Product contained in such Combination Product if such License Product is sold separately in finished form in such country, and B is the weighted average invoice price paid for such
Combination Product in such country. If such Licensed Product is not sold separately in finished form in such country, the parties shall determine Net Sales for such Licensed Product by mutual agreement based on the relative contribution of such
Licensed Product and each such other active ingredients in such Combination Product in accordance with the above formula, and shall take into account in good faith any applicable allocations and calculations that may have been made for the same
period in other countries. 
  

 3 

 LICENSE AGREEMENT 

 

 1.16 “Phase III Trial” means a human clinical trial of a Licensed Product
on a sufficient number of subjects that is designed to establish that a pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions and adverse reactions that are associated with such pharmaceutical
product in the dosage range to be prescribed, which trial is intended to support regulatory approval of a Licensed Product, all as described in 21 C.F.R. 312.21(c). For purposes of this Agreement, “Initiation of Phase III Trial”
for a Licensed Product means the first dosing of such Licensed Product in a human patient in a Phase III Trial. 
 1.17
“Technology” means know-how, trade secrets, chemical and biological materials, formulations, information, documents, studies, results, data and regulatory approvals, data, filings and correspondence (including DMFs), including biological,
chemical, pharmacological, toxicological, pre-clinical, clinical and assay data, manufacturing processes and data, specifications, sourcing information, assays, and quality control and testing procedures, whether or not patented or patentable.

 1.18 “Third Party” means any person or entity other than Aegerion or Bayer or any of their Affiliates. 

1.19 “Valid Claim” means a claim of an issued and unexpired patent contained within the Bayer Patent Rights, which claim has
not been revoked or held invalid or unenforceable by a court or other government agency of competent jurisdiction from which no appeal can be or has been taken and has not been held or admitted to be invalid or unenforceable through re-examination,
disclaimer, reissue, opposition procedure, nullity suit or otherwise, and which claim covers a Licensed Product or its use. 
 Section 2.
License Grant by Bayer. 
 2.1 Exclusive License. Bayer, for itself and on behalf of its Affiliates, hereby grants
to Aegerion and its Affiliates a non-transferable (except in accordance with Section 10.1), exclusive (even as to Bayer and its Affiliates), worldwide license, with the right to sublicense in accordance with Section 2.2 only, under the
Bayer Patent Rights and Bayer Know-How, to make, have made, use, sell, offer to sell, import, research, develop, commercialize and otherwise exploit Licensed Compounds and Licensed Products and Improvements (but with respect to Improvements, only to
the extent that any such Improvement is used in connection with the foregoing licensed activities involving Licensed Compounds and Licensed Products). The foregoing license grant includes the right to make reference to all regulatory approvals,
data, filings and correspondence (including DMFs) contained within the Bayer Know-How. 
  

 4 

 LICENSE AGREEMENT 

 

 2.2 Sublicenses. 

(a) Subject to Section 2.3, the exclusive license contained in Section 2.1 includes the right to grant
sublicenses (through multiple tiers) to Third Parties (each such Third Party sublicensee, a “Sublicensee”), provided that Aegerion shall remain responsible for the performance of its Sublicensees hereunder. Aegerion shall provide
Bayer with a copy of the sublicense agreement for its Sublicensees within ninety (90) days of execution, which copy may be redacted to exclude financial and other sensitive terms and shall be treated as Confidential Information of Aegerion
hereunder. 
 (b) Each sublicense granted by Aegerion to any rights licensed to it hereunder shall terminate
immediately upon the termination of the license from Bayer to Aegerion with respect to such rights, provided that such sublicensed rights shall not terminate if, as of the effective date of such termination by Bayer pursuant to Section 9.2, a
Sublicensee is not in material default of its obligations to Aegerion under its sublicense agreement, and within thirty (30) days of such termination the Sublicensee agrees in writing to be bound directly to Bayer under a license agreement
substantially similar to this Agreement with respect to the rights sublicensed hereunder, substituting such Sublicensee for Aegerion. 

2.3 Bayer First Right of Negotiation. In the event Aegerion desires at any time to have a Third Party sell one or more Licensed
Products after their respective First Commercial Sale in a particular country or countries (a “Commercialization Agreement”), Aegerion shall notify Bayer of its desire and provide Bayer with written notice specifying the applicable
Licensed Product(s) and country(ies). If Bayer notifies Aegerion in writing of its election to pursue a Commercialization Agreement for such Licensed Product(s) in such country(ies) within thirty (30) days of Bayer’s receipt of such
notice, Aegerion and Bayer shall enter into good faith negotiations with respect to such Commercialization Agreement for a period of ninety (90) days following Aegerion’s receipt of such election from Bayer (the “Negotiation
Period”). During the Negotiation Period, Aegerion shall provide Bayer with such information Controlled by Aegerion regarding such Licensed Product(s) as Bayer may reasonably request. If Aegerion and Bayer fail to enter into such
Commercialization Agreement (notwithstanding those good faith negotiations), or if Bayer fails to notify Aegerion in writing of Bayer’s election to initiate the Negotiation Period within such 30-day period, Aegerion shall thereafter be free to
negotiate and enter into a Commercialization Agreement with one or more Third Parties for some or all of such Licensed Product(s) and country(ies), without any further obligation or liability to Bayer. Bayer’s rights under this Section 2.3
shall not apply to any assignment by Aegerion permitted by Section 10.1, and this Section 2.3 shall terminate in full upon any such permitted assignment by Aegerion to a non-Affiliated Third Party. 

2.4 Restrictions on Bayer. 

(a) Bayer and its Affiliates shall not grant or provide to any Third Party any Technology, patent or other intellectual
property rights or Confidential Information inconsistent with the terms of this Agreement. For as long as the license grant set forth in Section 2.1 is in effect, (i) Bayer Know-How shall be treated as Confidential Information of both
Aegerion and Bayer, and Bayer and its Affiliates shall not disclose Bayer Know-How except as permitted by Sections 7.1(b) or 7.1(c), and (ii) Bayer and its Affiliates shall not provide to any person or entity (other than
Aegerion) any Licensed Compounds whose use or sale infringes a Valid Claim. 
 (b) The Parties acknowledge that
Bayer and its Affiliates do not currently have any MTP inhibitor program under development and currently do not anticipate initiating any such program. Furthermore, Bayer and its Affiliates do not currently, nor do they intend to, assist any Third
Party in developing any MTP inhibitors. Notwithstanding the foregoing, except as otherwise prohibited by the terms of this Agreement, Bayer reserves the right to do research and development in the area of MTP inhibitors after the Effective Date.

  

 5 

 LICENSE AGREEMENT 

 

 2.5 License Limitations. No licenses or other rights are granted by Bayer
hereunder to use any trademark, trade name, trade dress or service mark owned or otherwise Controlled by Bayer or any of its Affiliates. All licenses and other rights are or shall be granted only as expressly provided in this Agreement, and no other
licenses or other rights is or shall be created or granted hereunder by implication, estoppel or otherwise. 
 Section 3. Transfer of Bayer
Know-How. 
 3.1 Documentation. During the thirty (30) day period following the Effective Date, Bayer shall
provide to Aegerion one (1) electronic copy of all documents, data or other information listed on Exhibit A. 

3.2 Purchase of Licensed Compound. During the eighteen (18) month period following the Effective Date, Aegerion shall have
the right, but not the obligation, to purchase and have transferred from Bayer, in accordance with Aegerion’s directions, any portion of Bayer’s inventory of Licensed Compound from any batch that Aegerion may specify at a rate of one
thousand five hundred Euros (€1,500) per kilogram of Licensed Compound. The foregoing right shall apply with respect to any batch of Bayer’s inventory of Licensed Compound set forth in Exhibit C. During such eighteen
(18) month period, Bayer shall transfer to Aegerion, at Aegerion’s reasonable request, representative samples of Bayer’s inventory of License Compound from any such batch that Aegerion may specify for the purpose of testing such
samples for viability (at Aegerion’s cost). With respect to any remaining inventory of Licensed Compound in Bayer’s or any of its Affiliates’ possession, (i) Bayer shall not, and shall cause its Affiliates not to, use or transfer
to Third Parties any of such remaining inventory for any purpose and (ii) during such eighteen-month period, [CONFIDENTIAL TREATMENT REQUESTED] /*/. Bayer represents and warrants that (1) all of Bayer’s inventory of Licensed Compound
has been manufactured in accordance with GMP, (2) Exhibit C contains a complete and accurate list of all batches of such inventory as of the Effective Date, including accurate information related thereto, and (3) each batch of all
such inventory has a remaining shelf life as of the Effective Date equal to the period of time between the Effective Date and the “Retest date” set forth in Exhibit C for such batch. 

3.3 Technical Assistance. During the six (6) month period following the Effective Date, Bayer shall reasonably cooperate with
Aegerion to (i) provide (a) up to seventy (70) hours of technical assistance without charge to Aegerion and (b) any additional hours of technical assistance as Aegerion may reasonably request, for which Aegerion shall pay Bayer a
rate of [CONFIDENTIAL TREATMENT REQUESTED] /*/ U.S. dollars (US$ [CONFIDENTIAL TREATMENT REQUESTED] /*/) per hour of such technical assistance, and (ii) transfer to Aegerion any additional Bayer Know-How licensed under Section 2.1, in each
case to facilitate the transfer of development efforts related to Licensed Compounds and Licensed Products. Such cooperation shall include providing Aegerion with reasonable access by teleconference or in-person at Bayer’s facilities to Bayer
personnel involved in the research and development of Licensed Compounds and Licensed Products to provide Aegerion with a reasonable level of technical assistance and consultation in connection with the transfer of Bayer Know-How. 

 

 6 

 LICENSE AGREEMENT 

 

 Section 4. Development and Commercialization. 

4.1 Commercially Reasonable Efforts. Aegerion, or one of its Affiliates or Sublicensees, as applicable, shall use Commercially
Reasonable Efforts to develop and commercialize at least one Licensed Product. 
 4.2 Responsibilities and Costs.
Aegerion shall have sole responsibility for, and shall bear all its costs of conducting, all development and commercialization of Licensed Compounds and Licensed Products (including manufacturing all required materials, filing for and obtaining
all required regulatory approvals and submitting any adverse event reports to the applicable regulatory authority). Aegerion shall own the results of all such activities, and as between the Parties, all such regulatory approvals shall be obtained by
and in the name of Aegerion (or its Affiliates or Sublicensees). 
 4.3 Development Plan. Attached hereto as
Exhibit D is a summary of Aegerion’s initial “Development Plan,” which summarizes Aegerion’s plans for the development of Licensed Products. At least semi-annually until a marketing approval in a country for the first
Licensed Product, Aegerion shall provide to Bayer (i) any significant updates or revisions to the Development Plan for Bayer’s review (to the extent not prohibited by any agreement between Aegerion and a Sublicensee), and (ii) a
report presenting a meaningful summary of the development activities accomplished by Aegerion through the end of the preceding semi-annual period. Further, in the event Aegerion’s Board of Directors passes a final resolution to provide notice
of the discontinuation of the development of Licensed Compounds and Licensed Products hereunder, Aegerion shall notify Bayer in writing thereof within five (5) days of such final resolution, provided that such final resolution or
discontinuation of development shall not affect Aegerion’s rights hereunder. 
 Section 5. Aegerion Payments. 

5.1 Initial License Fee. Aegerion shall pay to Bayer seven hundred and fifty thousand U.S. dollars (US$750,000) within thirty
(30) days after the Effective Date. 
 5.2 Milestone Payments. As set forth in the following table, Aegerion shall
make Milestone Payments to Bayer upon achievement of each of the Milestones Events. Each Milestone Payment shall be payable by Aegerion to Bayer within thirty (30) days after the achievement of the corresponding Milestone Event with respect to the
first Licensed Product. Only one set of Milestone Payments are payable hereunder no matter how many times any of the Milestone Events are achieved. 
  

			
	 “Milestone Event”
	  	 “Milestone Payment”

		
	1. [CONFIDENTIAL TREATMENT REQUESTED] /*/	  	US$ [CONFIDENTIAL TREATMENT REQUESTED] /*/
		
	2. [CONFIDENTIAL TREATMENT REQUESTED] /*/	  	US$ [CONFIDENTIAL TREATMENT REQUESTED] /*/
		
	3. [CONFIDENTIAL TREATMENT REQUESTED] /*/	  	US$ [CONFIDENTIAL TREATMENT REQUESTED] /*/

5.3 Annual Payments. Aegerion shall pay to Bayer, within [CONFIDENTIAL TREATMENT REQUESTED] /*/ ([CONFIDENTIAL TREATMENT
REQUESTED] /*/) days after the start of the 
  

 7 

 LICENSE AGREEMENT 

 

 
corresponding calendar year, the following amounts, which amounts when paid shall be non-refundable: (i) for calendar year 2007, [CONFIDENTIAL TREATMENT REQUESTED] /*/ United States dollars
(US$ [CONFIDENTIAL TREATMENT REQUESTED] /*/), (ii) for calendar year 2008, [CONFIDENTIAL TREATMENT REQUESTED] /*/ United States dollars (US$ [CONFIDENTIAL TREATMENT REQUESTED] /*/), (iii) for calendar year 2009, [CONFIDENTIAL TREATMENT
REQUESTED] /*/ United States dollars (US$ [CONFIDENTIAL TREATMENT REQUESTED] /*/), (iv) for calendar year 2010, [CONFIDENTIAL TREATMENT REQUESTED] /*/ dollars (US$ [CONFIDENTIAL TREATMENT REQUESTED] /*/) and (v) for calendar year 2011,
[CONFIDENTIAL TREATMENT REQUESTED] /*/ United States dollars (US$ [CONFIDENTIAL TREATMENT REQUESTED] /*/) (each, an “Annual Payment”); provided, however, that each Annual Payment shall be creditable against the Milestone Payments as such
Milestone Payments become payable. [CONFIDENTIAL TREATMENT REQUESTED] /*/ 
 5.4 Commercialization
Milestone Payment. A one-time milestone payment of five million U.S. dollars (US$5,000,000) shall be payable by Aegerion to Bayer within thirty (30) days after the end of the calendar year in which Aegerion and its Affiliates and Sublicensees
first achieves aggregate Net Sales of all Licensed Products on which royalties are paid hereunder of two hundred fifty million U.S. dollars (US$250,000,000). 
  

 8 

 LICENSE AGREEMENT 

 

 5.5 Royalties. 

(a) Royalties. Subject to the terms and conditions of this Agreement (including the remainder of this Section
5), Aegerion shall pay to Bayer royalties, on a country-by-country and product-by-product basis for the period of time specified in Section 5.5(b), at the graduated royalty rates specified in the following table with respect to the aggregate
annual worldwide Net Sales of all Licensed Products in a calendar year: 
  

			
	 Aggregate Annual Worldwide Net Sales
of All Licensed Products in a Calendar Year
	  	 Royalty Rate

		
	On such Net Sales up to one hundred million U.S. dollars (US$100,000,000)	  	 [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent

([CONFIDENTIAL TREATMENT REQUESTED] /*/%)

		
	On such Net Sales above one hundred million U.S. dollars (US$100,000,000) and up to two hundred fifty million U.S. dollars (US$250,000,000)	  	[CONFIDENTIAL TREATMENT REQUESTED] /*/ ([CONFIDENTIAL TREATMENT REQUESTED] /*/%)
		
	On such Net Sales above two hundred fifty million U.S. dollars (US$250,000,000) and up to five hundred million U.S. dollars (US$500,000,000)	  	[CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%)
		
	On such Net Sales above five hundred million U.S. dollars (US$500,000,000)	  	[CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%)

The applicable royalty rate shall be determined by reference to all Net Sales on which royalties are paid in a given calendar year.
[CONFIDENTIAL TREATMENT REQUESTED] /*/ 
 (b) Royalty Term. The royalties due under Section 5.5(a)
shall be payable on Net Sales from the First Commercial Sale of a particular Licensed Product until the later of, on a country-by-country basis, (i) the expiration of the last to expire patent in such country within the Bayer Patent Rights
containing a Valid Claim covering such Licensed Product or its use for which regulatory approval has been obtained in such country, or (ii) ten (10) years from such First Commercial Sale, provided that such 10-year period shall apply only if
there was in such country a Valid Claim within the Bayer Patent Rights covering such Licensed Product or its use for which regulatory approval had been obtained in such country, and further provided that if royalties are owed on account of this
clause (ii) but not the preceding clause (i), the royalty rates specified in Section 5.5(a) shall be reduced by [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%). For clarity, only one 10-year
period under the foregoing clause (ii) above shall apply for all Licensed Products containing the same Licensed Compound (i.e., for a given chemical entity, not including all of the variations thereof identified in clause (b) of the
“Licensed Compound” definition). 
  

 9 

 LICENSE AGREEMENT 

 

 (c) Generic Competition. The royalty rates specified in
Sections 5.5(a) and 5.5(b) shall be reduced by [CONFIDENTIAL TREATMENT REQUESTED] /*/ ([CONFIDENTIAL TREATMENT REQUESTED] /*/) on a country-by-country basis at any such time where the sale of one or more Generic Product(s) in such country
exceeds [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of the unit sales volume for the applicable Licensed Product in that country, as measured by IMS Health or its successor. Such reduction shall be first
applied with respect to such country starting with sales in the calendar quarter following the first calendar quarter where the sales of the Generic Product(s) in such country exceed [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL
TREATMENT REQUESTED] /*/%) of the unit sales volume of the applicable Licensed Product. 
 (d) Only One
Royalty. Only one royalty shall be due with respect to the sale of the same unit of Licensed Product. Only one royalty shall be due hereunder on the sale of a Licensed Product even if the manufacture, use, sale, offer for sale or importation of
such Licensed Product infringes more than one claim of the Bayer Patent Rights. 
 5.6 Credits and Reductions. The
following shall apply to amounts payable to Bayer hereunder: 
 (a) Dominated IP. [CONFIDENTIAL TREATMENT
REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of third party royalties and milestones of actual costs paid or payable by Aegerion and its Affiliates for licenses and acquisitions by Aegerion, its Affiliates or Sublicensees of
patent or other intellectual property rights dominating or dominated by Bayer Patent Rights and therefore necessary to practice some or all of the Bayer Patent Rights in a particular country shall be creditable against payments owed Bayer under
Sections 5.2 to 5.5. 
 (b) Other IP. Third party royalties and milestones (other than as
credited under Section 5.6(a)) for the actual costs paid or payable by Aegerion and its Affiliates for licenses and acquisitions by Aegerion, its Affiliates or Sublicensees of patent or other intellectual property rights reasonably necessary
for the manufacture, use, sale, offer for sale or importation of any Licensed Product in a particular country shall be creditable against payments owed Bayer under Sections 5.2 to 5.5, provided that, in the case of royalties, only where
the aggregate royalty burden for such Licensed Product in a particular country exceeds [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of the Blended Rate (as defined below) and in such a royalty case,
Aegerion will be entitled to a credit in the amount of [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of such excess. For purposes of this Agreement, “Blended Rate” means (1) the total
amount of royalties that would be payable in the applicable calendar quarter and prior three (3) calendar quarters with respect to the applicable Licensed Product under Section 5.5 (without any reduction under this Section 5.6),
divided by (2) the total Net Sales on which royalties are paid for such Licensed Product for that same period, expressed as a percentage. 

Notwithstanding the foregoing provisions of this Section 5.6 or Sections 6.3(c) or 6.4, in no event shall Bayer receive
less than [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of the aggregate original payments due hereunder under Sections 5.2 to 5.5 for any given calendar quarter (with any unused credits to
accumulate and be applied against future payments due to Bayer). 
 5.7 Payment Terms. 

(a) Manner of Payment. All payments to be made by Aegerion hereunder shall be made in U.S. dollars by wire transfer
to such bank account as Bayer may designate. 
 (b) Reports and Royalty Payments. For as long as royalties
are due under Section 5.5(a), Aegerion shall furnish to Bayer a written report, within forty-five (45) days after the end of each calendar quarter, showing the amount of Net Sales of Licensed Products and royalty due for such calendar
quarter. 
  

 10 

 LICENSE AGREEMENT 

 

 
Royalty payments for each calendar quarter shall be due at the same time as such written report for the calendar quarter. The report shall include, at a minimum, the following information for the
applicable calendar quarter, each listed by product and by country of sale: (i) the number of units of Licensed Products sold by Aegerion and its Affiliates and Sublicensees on which royalties are owed Bayer hereunder; (ii) the gross
amount received for such sales; (iii) deductions taken from Net Sales as specified in the definition thereof; (iv) Net Sales; (v) the amounts of any credits or reductions permitted by Section 5.6 or elsewhere hereunder;
(vi) the royalties and Milestone Payments owed to Bayer, listed by category; and (vii) the computations for any applicable currency conversions pursuant to Section 5.7(d). Aegerion shall use commercially reasonable efforts to obtain
permission from each Sublicensee to share with Bayer the information listed in the foregoing clauses (other than clause (iv)) as it relates to Net Sales made by such Sublicensee, and to the extent successful, will include such Sublicensee
information in such report. All such reports shall be treated as Confidential Information of Aegerion. 
 (c)
Records and Audits. Aegerion shall keep, and shall cause each of its Affiliates and Sublicensees, as applicable, to keep adequate books and records of accounting for the purpose of calculating all royalties payable to Bayer hereunder. For the
two (2) years next following the end of the calendar year to which each shall pertain, such books and records of accounting (including those of Aegerion’s Affiliates and Sublicensees, as applicable) shall be kept at each of their principal
place of business and shall be open for inspection at reasonable times and upon reasonable notice by an independent certified accountant selected by Bayer, and which is reasonably acceptable to Aegerion, for the sole purpose of inspecting the
royalties due to Bayer under this Agreement. In no event shall such inspections be conducted hereunder more frequently than once every twelve (12) months. Such accountant must have executed and delivered to Aegerion and its Affiliates and
Sublicensees, as applicable, a confidentiality agreement as reasonably requested by Aegerion, which shall include provisions limiting such accountant’s disclosure to Bayer to only the results and basis for such results of such inspection. The
results of such inspection, if any, shall be binding on both Parties. Any underpayments shall be paid by Aegerion within thirty (30) days of notification of the results of such inspection. Any overpayments shall be fully creditable against
amounts payable in subsequent payment periods. Bayer shall pay for such inspections, except that in the event there is any upward adjustment in aggregate royalties payable for any calendar year shown by such inspection of more than [CONFIDENTIAL
TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of the amount paid, Aegerion shall reimburse Bayer for any reasonable out-of-pocket costs of such accountant. Any underpayments or overpayments under this
Section 5.7(c) shall be subject to the currency exchange provisions set forth in Section 5.7(d) as applied to the calendar quarter during which the royalty obligations giving rise to such underpayment or overpayment were incurred by
Aegerion. 
 (d) Currency Exchange. With respect to Net Sales invoiced in U.S. dollars, the Net Sales and
the amounts due to Bayer hereunder shall be expressed in U.S. dollars. With respect to Net Sales invoiced in a currency other than U.S. dollars, the Net Sales shall be expressed in the domestic currency of the entity making the sale, together with
the U.S. dollar equivalent, calculated using the official rate of exchange of such domestic currency as quoted by the Wall Street Journal, New York edition, for the last business day of the calendar quarter for which the payment is made. 

(e) Tax Withholding; Value-Added Tax. Aegerion shall have the right to withhold from payments due hereunder any tax
which Bayer is liable to under the appropriate tax laws and for the payments of which Aegerion is responsible. Bayer shall be sent tax receipts by Aegerion certifying the payments of the tax, so that Bayer may use it for claiming a credit on the tax
payable by Bayer in Germany on such payments. No deduction shall be made or a reduced amount shall be deducted if Bayer furnishes a document from all required tax authorities to Aegerion sufficiently before the due date of the payments, certifying
that the payments are exempt from tax or subject to a reduced tax rate according to the applicable convention for the avoidance of double taxation. Except for such withholding taxes and except for the personal corporate income tax of Bayer, any
other taxes, assessments, fees and charges 
  

 11 

 LICENSE AGREEMENT 

 

 
imposed against payments due to Bayer hereunder shall be borne by Aegerion. Besides the above said, both Parties will undertake commercially reasonable efforts to minimize the allover tax burden
for each of the Parties. Value-added tax shall apply as legally required. 
 (f) Interest Due. Aegerion
shall pay Bayer interest on any payments that are not paid on or before the date such payments are due under this Agreement at a rate of [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) per month or the
maximum applicable legal rate, if less, calculated on the total number of days payment is delinquent. 
 Section 6. Patent Prosecution,
Infringement and Extensions. 
 6.1 Appointment and Cooperation. With respect to all of the rights and activities of
Aegerion set forth in this Section 6, Bayer hereby appoints Aegerion as its agent for such purposes with the authority to act on Bayer’s behalf with respect to the Bayer Patent Rights. Bayer shall cooperate with Aegerion in the exercise of
Aegerion’s authority granted herein, and shall execute such documents and take such additional action as Aegerion may request in connection therewith. The Parties shall update Exhibits B-1 and B-2 upon either
Party’s reasonable request. 
 6.2 Prosecution and Maintenance. 

(a) By Aegerion. On the Effective Date, Bayer shall provide Aegerion with copies of the complete prosecution files
for all patents and patent applications listed on Exhibit B. Aegerion shall be solely responsible for the preparation, prosecution (including any interferences, oppositions, reissue proceedings and reexaminations) and maintenance of the
Bayer Patent Rights, and all filing, prosecution, and maintenance decisions with respect to the Bayer Patent Rights shall be made by Aegerion, provided Bayer shall retain the right to give comments to Aegerion on material aspects of those
activities. Aegerion shall be responsible for all its costs incurred for such preparation, prosecution and maintenance. Each Party shall provide to the other Party copies of any papers relating to the filing, prosecution or maintenance of Bayer
Patent Rights promptly upon receipt. Bayer shall not take any action with respect to the prosecution or maintenance of any Bayer Patent Rights without the prior written consent of Aegerion, except as contemplated by Section 6.2(b). 

(b) By Bayer. Aegerion shall not knowingly permit any of the Bayer Patent Rights to be abandoned in any country
without Bayer first being given an opportunity to assume full responsibility for the continued prosecution and maintenance of same. In the event that Aegerion decides not to continue the prosecution or maintenance of a patent application or patent
within Bayer Patent Rights in any country, Aegerion shall provide Bayer with notice of this decision at least thirty (30) days prior to any pending lapse or abandonment thereof. In the event that Bayer elects to assume responsibility for such
prosecution and maintenance within thirty (30) days of Aegerion’s notice, Section 6.2(a) shall thereafter apply to such patent application(s) and patent(s) except that the role of Aegerion and Bayer shall be reversed thereunder
(including that Bayer shall be solely responsible for all costs arising from those activities). Such patent application(s) and patent(s) shall otherwise continue to be subject to all of the terms and conditions of the Agreement in the same way as
the other Bayer Patent Rights. 
 (c) Bayer Improvement Patents. For any Bayer Improvement Patents, the
roles of the Parties under this Sections 6.2 shall be reversed. 
 6.3 Enforcement and Defense. 

(a) By Aegerion. In the event that Bayer or Aegerion becomes aware of a suspected infringement of any Bayer Patent
Right, or any such Bayer Patent Right is challenged in any action or proceeding (other than any interferences, oppositions, reissue proceedings or reexaminations, which are addressed above), such Party shall notify the other Party promptly, and
following such notification, the Parties shall confer. Aegerion shall have the right, but shall not be obligated, to defend any such action or 

 

 12 

 LICENSE AGREEMENT 

 

 
proceeding or bring an infringement action with respect to such infringement at its own expense, in its own name and entirely under its own direction and control, or settle any such action or
proceeding by sublicense. Bayer shall reasonably assist Aegerion in any action or proceeding being defended or prosecuted if so requested, and shall join such action or proceeding if reasonably requested by Aegerion or required by applicable law.
Bayer shall have the right to participate in any such action or proceeding with its own counsel at its own expense and without reimbursement. 

(b) By Bayer. If Aegerion elects not to settle, defend or bring any action for infringement described in
Section 6.3(a) and so notifies Bayer, then, if and only if such infringement would give rise to royalties payable to Bayer hereunder had Aegerion conducted the alleged infringing activities, Bayer may defend or bring such action at its own
expense, in its own name and entirely under its own direction and control, subject to the following: Aegerion shall reasonably assist Bayer in any action or proceeding being defended or prosecuted if so requested, and shall join such action or
proceeding if requested by Bayer or required by applicable law. Aegerion shall have the right to participate in any such action or proceeding with its own counsel at its own expense and without reimbursement. No settlement of any such action or
proceeding which restricts the scope, or adversely affects the enforceability, of a Bayer Patent Right may be entered into by Bayer without the prior written consent of Aegerion. 

(c) Escrow in Certain Circumstances. On a country-by-country and product-by-product basis, in any action or
proceeding in which a Third Party challenges the validity or enforceability of all (and not less than all) of the Valid Claims under the Bayer Patent Rights in such country that cover such Licensed Product or its use (including by way of
interference, opposition, reissue proceeding or reexamination, or in response to enforcement pursuant to Section 6.3), then upon filing of such action or proceeding by a Third Party, fifty percent (50%) of all the royalties which would
otherwise be paid to Bayer, with respect to such Licensed Product for such country affected by such action or proceeding, shall be deposited in an interest bearing escrow account, until such time as all such Valid Claims expire. All monies in such
escrow account, together with all accrued interest, shall be retained by Aegerion if all such Valid Claims are found invalid or unenforceable by a court of proper jurisdiction in a decision unappealable or unappealed within the time allowed for
appeal, and, if at least one such Valid Claim is found not invalid and not unenforceable by a court of proper jurisdiction in such a decision, all monies in such escrow account, together with all accrued interest, shall be released to Bayer
immediately. 
 (d) Withdrawal. If either Party brings an action or proceeding under this Section 6.3
and subsequently ceases to pursue or withdraws from such action or proceeding, it shall promptly notify the other Party and the other Party may substitute itself for the withdrawing Party under the terms of this Section 6.3. 

(e) Damages. In the event that either Party exercises the rights conferred in this Section 6.3 and recovers
any damages or other sums in such action or proceeding or in settlement thereof, such damages or other sums recovered shall first be applied to all out-of-pocket costs and expenses incurred by the Parties in connection therewith (including attorneys
fees), unless not reimbursable hereunder. If such recovery is insufficient to cover all such costs and expenses of both Parties, the controlling Party’s costs shall be paid in full first before any of the other Party’s costs. If after such
reimbursement any funds shall remain from such damages or other sums recovered, [CONFIDENTIAL TREATMENT REQUESTED] /*/. 

 

 13 

 LICENSE AGREEMENT 

 

 6.4 Third Party IP Claims. In the event of (i) a holding in any action or
proceeding enjoining Aegerion or any of its Affiliates or Sublicensees from manufacturing, using, selling, offering for sale, importing, developing or commercializing any Licensed Compounds or Licensed Products, or holding Aegerion or any such other
entities liable for damages for any such activities, in each case such holding unappealable or unappealed within the time allowed for appeal, or (ii) a settlement of any action or proceeding requiring payment of damages by Aegerion or any such
party, Bayer shall refund to Aegerion royalties paid with respect to all Licensed Products affected by such action or proceeding, from the time such action or proceeding is first brought, sufficient to reimburse Aegerion and all such entities for
[CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of all damages and costs and expenses paid or incurred by any of them with respect to such action or proceeding attributable to infringement or
misappropriation of any Third Party’s patent or other intellectual property rights, provided that in no event shall Bayer be required to refund more than [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED]
/*/%) of any such royalties paid by Aegerion, and provided further, in the event that such refund is not sufficient to compensate for such [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of all such
damages and expenses, Aegerion shall be entitled to reduce royalties payable to Bayer by up to [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) hereunder in each subsequent calendar quarter until such
time as Aegerion recovers in full such [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of all such damages and expenses. 

6.5 Patent Extensions; Orange Book Listings; Patent Certifications. 

(a) Patent Term Extension. If elections with respect to obtaining patent term extension or supplemental protection
certificates or their equivalents in any country with respect to Bayer Patent Rights or other patent rights covering Licensed Products or their manufacture or use are available, Aegerion shall have the sole right to make any such elections.

 (b) Data Exclusivity and Orange Book Listings. With respect to data exclusivity periods (such as those
periods listed in the FDA’s Orange Book (including any available pediatric extensions) or periods under national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83, and all equivalents in any country), Aegerion shall have the sole
right to seek and maintain all such data exclusivity periods available for the Licensed Products. 
 (c)
Notification of Patent Certification. Bayer shall notify and provide Aegerion with copies of any allegations of alleged patent invalidity, unenforceability or non-infringement of a Bayer Patent Right pursuant to a Paragraph IV Patent
Certification by a Third Party filing an Abbreviated New Drug Application, an application under §505(b)(2) of the United States Federal Food, Drug, and Cosmetic Act, as amended, or any other similar patent certification by a Third Party, and
any foreign equivalent thereof. Such notification and copies shall be provided to Aegerion within two (2) days after Bayer receives such certification, and shall be sent to the address set forth in Section 10.5. 

Section 7. Confidential Information and Publicity. 

7.1 Confidentiality. 

(a) Confidential Information. Except as expressly provided herein, each of the Parties agrees that, for itself and
its Affiliates, and for as long as this Agreement is in effect and for a period of 
  

 14 

 LICENSE AGREEMENT 

 

 
ten (10) years thereafter, a Party and its Affiliates (the “Receiving Party”) receiving Confidential Information of the other Party or its Affiliates
(the “Disclosing Party”) shall (i) not disclose such Confidential Information to any Third Party without the prior written consent of the Disclosing Party, except for disclosures expressly permitted below, and (ii) not use
such Confidential Information for any purpose except those licensed or otherwise authorized or permitted by this Agreement. For clarity, all Confidential Information of Aegerion received by or disclosed to Bayer hereunder shall be used by Bayer only
for ensuring that Aegerion complies with its obligations hereunder and for no other purposes. 
 (b)
Exceptions. The obligations in Section 7.1(a) shall not apply with respect to any portion of the Confidential Information that the Receiving Party can show by competent proof: 

(i) is publicly disclosed by the Disclosing Party, either before or after it is disclosed to the Receiving Party
hereunder; 
 (ii) was known to the Receiving Party or any of its Affiliates, without any obligation to keep it
confidential or any restriction on its use, prior to disclosure by the Disclosing Party; 
 (iii) is subsequently
disclosed to the Receiving Party or any of its Affiliates by a Third Party lawfully in possession thereof and without any obligation to keep it confidential or any restriction on its use; 

(iv) is published by a Third Party or otherwise becomes publicly available or enters the public domain, either before or
after it is disclosed to the Receiving Party; or 
 (v) has been independently developed by employees or
contractors of the Receiving Party or any of its Affiliates without the aid, application or use of Confidential Information of the Disclosing Party. 

(c) Authorized Disclosures. The Receiving Party may disclose Confidential Information belonging to the Disclosing
Party to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances: 

(i) subject to Section 7.2, by either Party in order to comply with applicable non-patent law (including any
securities law or regulation or the rules of a securities exchange) and with judicial process, if in the reasonable opinion of the Receiving Party’s counsel, such disclosure is necessary for such compliance; 

(ii) by either Party, in connection with prosecuting or defending litigation, making regulatory filings, and filing,
prosecuting and enforcing patent applications and patents (including Bayer Patent Rights in accordance with Section 6); 

(iii) by Aegerion, to its Affiliates, potential and future collaborators (including Sublicensees), permitted acquirers or
assignees under Section 10.1, research collaborators, subcontractors, investment bankers, investors, lenders, and their and each of Aegerion and its Affiliates’ respective directors, employees, contractors and agents; and 

(iv) by Bayer to its Affiliates, permitted acquirers or assignees under Section 10.1, investment bankers, investors,
lenders, and their and Bayer and its Affiliates’ respective directors, employees, contractors and agents, 
 provided that (1) with
respect to Section 7.1(c)(i) or 7.1(c)(ii), where reasonably possible, the Receiving Party shall notify the Disclosing Party of the Receiving Party’s intent to make any disclosure pursuant thereto sufficiently prior to making such
disclosure so as to allow the Disclosing Party adequate time to take whatever action it may deem appropriate to protect the confidentiality of the information to be disclosed, and (2) with respect to Sections 7.1(c)(iii)
and 7.1(c)(iv), each of those named people and entities must be bound prior to disclosure by confidentiality and non-use restrictions at least as restrictive 

 

 15 

 LICENSE AGREEMENT 

 

 
as those contained in this Section 7 (other than investment bankers, investors and lenders, who must be bound prior to disclosure by commercially reasonable obligations of confidentiality).
In addition to the foregoing, Aegerion and its Affiliates and Sublicensees may make such disclosures of Bayer Know-How specifically concerning the Licensed Compound and its use as any of them may deem reasonably necessary for their business.

 7.2 Terms of this Agreement; Publicity. 

(a) The Parties agree that the terms of this Agreement shall be treated as Confidential Information of both Parties, and
thus may be disclosed only as permitted by Section 7.1(c). Each Party agrees not to issue any press release or public statement disclosing information relating to this Agreement or the transactions contemplated hereby or the terms hereof
without the prior written consent of the other Party (or as such consent may be obtained in accordance with Section 7.2(b)), which consent shall not be unreasonably withheld, or as permitted by Section 7.1(c). 

(b) In the event either Party (the “Issuing Party”) desires to issue a press release or other public
statement disclosing information relating to this Agreement or the transactions contemplated hereby or the terms hereof, the Issuing Party shall provide the other Party (the “Reviewing Party”) with a copy of the proposed press
release or public statement (the “Release”). The Reviewing Party shall have three (3) business days to provide any comments on such Release, and if the Receiving Party fails to provide any comments during such three-day
period, the Reviewing Party shall be deemed to have consented to the issuance of such Release. If the Receiving Party provides any comments, the Parties shall consult on the such Release and work in good faith to prepare a mutually acceptable
Release. Either Party may subsequently publicly disclose any information previously contained in any Release so consented to. 

7.3 Relationship to the Confidentiality Agreement. This Agreement supersedes the Confidentiality Agreement, provided that
all “Confidential Information” disclosed or received by the Parties thereunder shall be deemed “Confidential Information” hereunder and shall be subject to the terms and conditions of this Agreement. 

Section 8. Warranties; Limitations of Liability; Indemnification 

8.1 Bayer Representations and Warranties. Bayer covenants, represents and warrants to Aegerion that as of the Effective Date:

 (a) Bayer is a corporation duly organized, validly existing and in good standing under the laws of state or
jurisdiction in which it is incorporated, and it has full right and authority to enter into this Agreement and to grant the licenses and other rights to Aegerion as herein described. 

(b) This Agreement has been duly authorized by all requisite corporate action, and when executed and delivered will become
a valid and binding contract of Bayer enforceable against Bayer in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium and other law affecting creditors’ rights generally from time to time if
effect, and to general principles of equity. 
 (c) The execution, delivery and performance of this Agreement
does not conflict with any other agreement, contract, instrument or understanding, oral or written, to which Bayer is a party, or by which it is bound, nor will it violate any law applicable to Bayer. 

(d) All necessary consents, approvals and authorizations of all regulatory and governmental authorities and other persons
or entities required to be obtained by Bayer in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained. 

(e) Exhibit A contains a list of all Bayer Know-How in Bayer’s possession as of the Effective Date that Bayer
has reasonably concluded Aegerion will find reasonably necessary or useful for 
  

 16 

 LICENSE AGREEMENT 

 

 
the manufacture, use, sale, offer for sale, importation, research, development or commercialization or other exploitation of any Licensed Compounds or Licensed Products or Improvements. Attached
hereto as Exhibit B is a complete and accurate list of all patents and patent applications owned (in whole or in part) or otherwise Controlled by Bayer or any of its Affiliates that the manufacture, use, sale, offer for sale or
importation of any Licensed Compounds (alone or as part of any Combination Product) would infringe. To the knowledge of Bayer, the issued claims included in the Bayer Patent Rights are valid and enforceable, and no written claim has been made
(except by a patent examiner during prosecution of the patent application(s) that resulted in any such issued patent claims), and no action or proceeding has been commenced or threatened, alleging to the contrary. Bayer is the sole and exclusive
owner of all right, title and interest in and to the Bayer Patent Rights. None of the Bayer Patent Rights or Bayer Know-How is subject to any lien, security interest or other encumbrance. To Bayer’s knowledge, the conception and reduction to
practice of the Bayer Patent Rights have not constituted or involved the misappropriation of trade secrets or other rights or property of any Third Party. There are no claims, judgments or settlements against or amounts with respect thereto owed by
Bayer or any of its Affiliates relating to the Bayer Patent Rights. To Bayer’s knowledge, there has been no infringement by any Third Party of any Bayer Patent Rights. The use or practice of the license grant contained in Section 2.1 shall
not trigger any payment obligation by Bayer or any of its Affiliates or Former Licensees (as defined below) to any Third Party. 

(f) There is no pending action or proceeding alleging, or, to Bayer’s knowledge, any written communication alleging,
that the manufacture, use, sale, offer for sale or importation of any Licensed Compounds (alone or as part of any Combination Product), the activities of Bayer or any of its Affiliates or any of their licensees with respect to any such Licensed
Compounds, or the practice or use of the Bayer Patent Rights or Bayer Know-How, has or will infringe or misappropriate any patent or other intellectual property rights of any Third Party. Bayer has notified Aegerion of all such rights of any Third
Party of which Bayer is aware that are related to the foregoing activities, including those patents set forth on Exhibit E-1. 

(g) Except as set forth in Exhibit E-2: 

(i) Pharmaceutical Product Development, Inc. (together with its affiliates, including Medical Research Laboratories
International, LLC, collectively “PPD”) and Evan Stein, MD, PhD (“Dr. Stein”) constitute all Former Licensees known to Bayer, wherein “Former Licensees” means Bayer’s former licensees under any Bayer Patent Rights
or Bayer Know-How with respect to any Licensed Compounds and their sublicensees, subcontractors, clinical partners and other collaborators. 

(ii) Since Bayer has not done an in-depth analysis of IP since 2002 when implitapide was originally out-licensed, Bayer
can only represent that to its knowledge in light of the gap identified, it has sufficient rights (by ownership or license) in and to all Former Licensees IP (as defined below) for all Former Licensee IP to be treated as Bayer Patent Rights and
Bayer Know-How hereunder (including being subject to the exclusive license grant contained in Section 2.1), wherein “Former Licensee IP” means all Technology and patent and other intellectual property rights created or owned or
otherwise Controlled by any Former Licensee or any of its Affiliates, in each case related to the manufacture, use, sale, offer for sale, importation, development or commercialization of any Licensed Compounds. Without limiting the generality of the
foregoing, and to Bayer’s knowledge, PPD does not retain any right, title or interest in or to any Former Licensee IP, and no Former Licensee has filed or obtained any patent rights concerning any of those activities. 

(iii) To the knowledge of Bayer, no Former Licensee has any supply of Licensed Compounds. 

(h) To the extent that Bayer has the benefit of any contractual rights from any Former Licensees concerning the
development or commercialization of any Licensed Compounds, Bayer shall 
  

 17 

 LICENSE AGREEMENT 

 

 
use commercially reasonable efforts to exercise the same on behalf of Aegerion or any of its Affiliates or Sublicensees upon request (or if not so commercially reasonable, shall transfer the
right to exercise the same to Aegerion or any of its Affiliates or Sublicensees as Aegerion may designate and as may be permitted by the applicable terms). 

(i) As of the Effective Date, except as set forth in Exhibit E-3, Bayer does not have any knowledge of any
scientific or clinical facts or circumstances that would materially and adversely affect the safety, efficacy or market performance of any Licensed Compounds (alone or as part of any Combination Product) that have not been communicated to Aegerion.

 8.2 Aegerion Representations and Warranties. Aegerion covenants, represents and warrants to Bayer that as of the
Effective Date: 
 (a) Aegerion is a corporation duly organized, validly existing and in good standing under the
laws of state in which it is incorporated, and it has full right and authority to enter into this Agreement and to accept the rights and licenses granted as herein described. 

(b) This Agreement has been duly authorized by all requisite corporate action, and when executed and delivered will become
a valid and binding contract of Aegerion enforceable against Aegerion in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium and other laws affecting creditors’ rights generally from time to time
if effect, and to general principles of equity. 
 (c) The execution, delivery and performance of this Agreement
does not conflict with any other agreement, contract, instrument or understanding, oral or written, to which Aegerion is a party, or by which it is bound, nor will it violate any law applicable to Aegerion. 

(d) All necessary consents, approvals and authorizations of all regulatory and governmental authorities and other persons
or entities required to be obtained by Aegerion in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained. 

8.3 Disclaimer. EXCEPT AS EXPRESSLY SET FORTH HEREIN, NEITHER BAYER NOR AEGERION MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR
IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 
 8.4 Limitation of Liability.
NOTWITHSTANDING ANYTHING IN THIS AGREEMENT OR OTHERWISE, NEITHER PARTY SHALL BE LIABLE TO THE OTHER OR ANY THIRD PARTY WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT FOR ANY INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES; PROVIDED, HOWEVER, THAT
THIS SECTION 8.4 SHALL NOT APPLY TO THE PARTIES’ INDEMNIFICATION RIGHTS AND OBLIGATIONS UNDER SECTIONS 8.6(a) AND 8.6(b). 

8.5 Performance by Affiliates. The Parties recognize that each Party may perform some or all of its obligations under this
Agreement through Affiliates and Third Party contractors provided, however, that each Party shall remain responsible and liable for the performance by its Affiliates and Third Party contractors and shall cause its Affiliates and Third Party
contractors to comply with the provisions of this Agreement in connection therewith. 
 8.6 Indemnification. 

(a) Aegerion Indemnity. Aegerion hereby agrees to indemnify and hold Bayer and its Affiliates, and their respective
employees, directors, agents and contractors, and their respective successors, heirs and assigns and representatives (“Bayer Indemnitees”) harmless from and against all claims, liability, threatened claims, damages, expenses (including
reasonable attorneys’ fees), suits, proceedings, losses or judgments, whether for money or equitable relief, of any kind, including death, 

 

 18 

 LICENSE AGREEMENT 

 

 
personal injury, illness, product liability or property damage or the failure to comply with applicable law (but not infringement or misappropriation of patents or other intellectual property
rights) (collectively, “Losses”), arising from any Third Party claim due to the use, manufacture, sale, development or commercialization of any Licensed Compounds or Licensed Products by or for Aegerion or any of its Affiliates,
Sublicensees, agents and contractors, except to the extent that such Losses arise from (a) the negligence, recklessness or willful misconduct of any Bayer Indemnitees or (b) any breach of this Agreement by Bayer. 

(b) Bayer Indemnity. Bayer hereby agrees to indemnify and hold Aegerion, its Affiliates and Sublicensees, and their
respective employees, directors, agents and contractors, and their respective successors, heirs and assigns and representatives (“Aegerion Indemnitees”) harmless from and against all Losses arising from any Third Party claim due to the
use, manufacture, sale, development or commercialization of any Licensed Compounds or Licensed Products by or for Bayer or any of its Affiliates, licensees (other than Aegerion and its Affiliates and Sublicensees), agents and contractors, except to
the extent that such Losses arise from (a) the negligence, recklessness or willful misconduct of any Aegerion Indemnitees or (b) any breach of this Agreement by Aegerion. 

(c) Indemnification Procedure. A claim to which indemnification applies under Section 8.6(a) or
Section 8.6(b) shall be referred to herein as a “Claim”. If any person or entity (each, an “Indemnitee”) intends to claim indemnification under this Section 8.6, the Indemnitee shall notify the other Party
(the “Indemnitor”) in writing promptly upon becoming aware of any claim that may be a Claim (it being understood and agreed, however, that the failure by an Indemnitee to give such notice shall not relieve the Indemnitor of its
indemnification obligation under this Agreement except and only to the extent that the Indemnitor is actually prejudiced as a result of such failure to give notice). The Indemnitor shall have the right to assume and control the defense of such Claim
at its own expense with counsel selected by the Indemnitor and reasonably acceptable to the Indemnitee; provided, however, that an Indemnitee shall have the right to retain its own counsel, with the fees and expenses to be paid by the Indemnitee, if
representation of such Indemnitee by the counsel retained by the Indemnitor would be inappropriate due to actual or potential differing interests between such Indemnitee and any other party represented by such counsel in such proceedings. If the
Indemnitor does not assume the defense of such Claim as aforesaid, the Indemnitee may defend such Claim but shall have no obligation to do so. The Indemnitee shall not settle or compromise any Claim without the prior written consent of the
Indemnitor, and the Indemnitor shall not settle or compromise any Claim in any manner which would have an adverse effect on the Indemnitee’s interests, without the prior written consent of the Indemnitee, which consent, in each case, shall not
be unreasonably withheld. The Indemnitee shall reasonably cooperate with the Indemnitor at the Indemnitor’s expense and shall make available to the Indemnitor all pertinent information under the control of the Indemnitee, which information
shall be subject to Section 7.1. 
 8.7 Insurance. Aegerion shall procure and maintain insurance policies for the
following coverages with respect to personal injury, bodily injury and property damage arising out of Aegerion’s performance under this Agreement: (a) during the term of this Agreement, comprehensive general liability, including broad form
and contractual liability, in a minimum amount of $3,000,000 combined single limit per occurrence and in the aggregate; (b) prior to the commencement of clinical trials involving any Licensed Products, clinical trials coverage in a minimum
amount of $5,000,000 combined single limit per occurrence and in the aggregate; and (c) prior to the First Commercial Sale of the first Licensed Product, product liability coverage, in a minimum amount of $2,000,000 combined single limit per
occurrence and in the aggregate, with the coverage provided for in clauses (b) and (c) to remain in force during the term of this Agreement and for at least five (5) years thereafter. The policies of insurance required by this
Section 8.7 shall be issued by an insurance carrier with an A.M. Best rating of “A” or better. Aegerion shall provide Bayer with insurance certificates evidencing the required coverage within thirty (30) days after the Effective
Date and the commencement of each policy period and any renewal periods. 
  

 19 

 LICENSE AGREEMENT 

 

 Section 9. Term, Termination and Survival. 

9.1 Term. This Agreement shall commence as of the Effective Date and, unless sooner terminated in accordance with the terms hereof
or by mutual written consent, shall continue on a country-by-country and product-by-product basis until the end of the period during which royalties are due hereunder on Net Sales of such Licensed Product in such country. Upon the end of such period
for such Licensed Product in such country, the license grant contained in Section 2.1 shall become perpetual, irrevocable and fully paid up with respect to such Licensed Product in such country. 

9.2 Termination for Material Default. Either Party shall have the right to terminate this Agreement upon delivery of written
notice to the other Party in the event of any default in the performance by such other Party of any of such other Party’s material obligations under this Agreement, provided that such default has not been cured within ninety (90) days, or, in
the event such default results in a failure to make payment when due hereunder, thirty (30) days, after written notice thereof is given by the non-defaulting Party to the defaulting Party specifying the nature of the alleged default, provided the
Parties shall take all reasonable steps to resolve the matter pursuant to the process set forth in Section 10.6(a) during the applicable cure period and before any such termination becomes effective. Termination of this Agreement by Bayer under
this Section 9.2 shall be on a country-by-country and product-by-product basis (and not for the Agreement as a whole) if the default giving rise to termination is reasonably specific to one or more countries or one or more products
(e.g., a royalty dispute for one product in one or more countries). 
 9.3 Termination for Convenience by
Aegerion. Aegerion may terminate this Agreement in full for any reason effective upon sixty (60) days prior written notice to Bayer. 

9.4 Termination for Insolvency. To the extent permitted by law, upon the filing or institution of bankruptcy, reorganization,
liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors (a “Bankruptcy Event”) by either Party, Bayer, in the case of a Bankruptcy Event by Aegerion, or
Aegerion, in the case of a Bankruptcy Event by Bayer, may terminate this Agreement; provided, however, that, in the case of any involuntary bankruptcy proceeding, such right to terminate shall only become effective if the subject Party consents to
the involuntary bankruptcy or such proceeding is not dismissed within ninety (90) days after the filing thereof. Each Party shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code and foreign
equivalents, including that upon commencement of a bankruptcy proceeding by or against such Party undergoing a bankruptcy proceeding (the “Affected Party”) under the U.S. Bankruptcy Code or foreign equivalents, the non-Affected Party
shall be entitled to complete duplicates of or complete access to, as such non-Affected Party deems appropriate, any Technology and patent and other intellectual property rights and all embodiments hereof licensed or to be transferred to such
non-Affected Party hereunder by the Affected Party. Such Technology, rights and embodiments shall be promptly delivered to the non-Affected Party (i) upon any such commencement of a bankruptcy proceeding and upon written request thereof by the
non-Affected Party, unless the Affected Party elects to continue to perform all of its obligations under this Agreement, or (ii) if not delivered under the foregoing clause (i), upon the rejection of this Agreement by or on
behalf of the Affected Party upon written request therefore by the non-Affected Party. This Section 9.4 is without prejudice to any rights the non-Affected Party may have arising under the U.S. Bankruptcy Code, foreign equivalents or other law.

  

 20 

 LICENSE AGREEMENT 

 

 9.5 Effect of Certain Terminations. Upon termination of this Agreement by Bayer
pursuant to Section 9.2 or 9.4 or by Aegerion pursuant to Section 9.3, or with respect to each applicable product and country as to which termination occurs pursuant to Section 9.2 (the rights and obligations of the Parties as to the
remaining products and countries in which termination under Section 9.2 has not occurred, being unaffected by such termination), all rights and licenses granted to Aegerion in Section 2 shall terminate with respect to each such terminated
product and country, with all rights of Aegerion under Bayer Patent Rights for each such terminated product and country reverting to Bayer, and Section 2.2(b) shall apply to all Sublicensees in each such terminated country for each such
terminated product. Further, upon any such termination and at Bayer’s reasonable request, on a country-by-country and product-by-product basis, Aegerion shall grant to Bayer a license to use, and shall provide to Bayer a copy of, all regulatory
approvals, data, filings and correspondence (including DMFs) then in Aegerion’s Control relating to such product and applicable to such country, but only for the continued development and commercialization of such product in such country, and
provided that (i) all such information shall be treated as Confidential Information of Aegerion hereunder, (ii) such license and use shall be subject to any rights of any Sublicensees that survive any such termination as contemplated by
Section 2.2(b) and this Section 9 (including, if such Sublicensee is an exclusive sublicensee for such product in such country, then there shall not be any such license nor any provision of such information by Aegerion but such Sublicensee
shall agree to be bound to Bayer in place of Aegerion for purposes of this sentence), and (iii) if such termination occurs after Aegerion or any of its Affiliates or Sublicensees has filed for an NDA or its foreign equivalent or has obtained
regulatory approval or has made a First Commercial Sale for such product in such country, then Bayer shall pay to Aegerion commercially reasonable royalties in an amount to be agreed to by the Parties on sales of such product in such country to
reflect the investment in and value contributed by Aegerion and its Affiliates and Sublicensees to the development and commercialization of such product. 

9.6 Right to Sell-Off Inventory. Upon termination of this Agreement for any reason, should Aegerion or any of its Affiliates or
Sublicensees have any inventory of any Licensed Product, each of them shall have six (6) months thereafter in which to dispose of such inventory (subject to the payment to Bayer of any royalties due hereunder thereon). 

9.7 Survival. In addition to the termination consequences set forth in Section 9.5, the following provisions shall
survive expiration or termination of this Agreement for any reason, as well as any other provision which by its terms or by the context thereof, is intended to survive such termination: Sections 2.2(b), 2.5, 5.5(d), 5.7,
6.3 (but only with respect to any action or proceeding initiated before such expiration or termination), 6.4, 8.3, 8.4, 8.5 and 8.6, and Section 1, Section 7, Section 9 and Section 10.
Expiration or termination of this Agreement for any reason shall not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination or expiration, nor preclude either Party from pursuing
all rights and remedies it may have hereunder or at law or in equity, subject to Section 10.6, with respect to any breach of this Agreement nor prejudice either Party’s right to obtain performance of any obligation. 

Section 10. General Provisions. 

10.1 Assignment. Except as expressly provided by Section 2.1, 2.2 or 8.5, neither Party may assign this Agreement, delegate
its obligations or otherwise transfer licenses or other rights created by this Agreement, without the prior written consent of the other Party, which consent shall not be unreasonably withheld; provided that each Party may assign this Agreement as a
whole without such consent to an Affiliate or in connection with the acquisition (whether by merger, consolidation, sale or otherwise) of such Party or of that part of such Party’s business to which this Agreement relates, provided that such
Party provides written notice to the other Party of such assignment and the assignee thereof agrees in writing to be bound as such Party hereunder. Any assignment or transfer in violation of this Section 10.1 shall be void. This Agreement shall
inure to the benefit of, and be binding upon, the legal representatives, successors and permitted assigns of the Parties. 
  

 21 

 LICENSE AGREEMENT 

 

 10.2 Force Majeure. Neither Party shall be held liable or responsible to the
other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement if, but only to the extent that, such failure or delay results from causes beyond the reasonable
control of the affected Party, potentially including fire, floods, embargoes, terrorism, war, acts of war (whether war be declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, acts of God or acts,
omissions or delays in acting by any governmental authority or any other Party; provided that the Party affected shall promptly notify the other of the force majeure condition and shall exert reasonable efforts to eliminate, cure or overcome any
such causes and to resume performance of its obligations as soon as possible. 
 10.3 Severability. If any one or more of
the provisions contained in this Agreement is held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless
the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties. The Parties shall in such an instance use their reasonable best efforts to replace the invalid, illegal or unenforceable provision(s) with valid,
legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement. 
 10.4 Amendment;
Waiver. This Agreement may not be modified, amended or rescinded, in whole or part, except by a written instrument signed by the Parties; provided that any unilateral undertaking or waiver made by one Party in favor of the other shall be
enforceable if undertaken in a writing signed by the Party to be charged with the undertaking or waiver. No delay or omission by either Party hereto in exercising any right or power occurring upon any noncompliance or default by the other Party with
respect to any of the terms of this Agreement shall impair any such right or power or be construed to be a waiver thereof. A waiver by either of the Parties of any of the covenants, conditions or agreements to be performed by the other shall not be
construed to be a waiver of any succeeding breach thereof or of any other covenant, condition or agreement herein contained. 
  

 22 

 LICENSE AGREEMENT 

 

 10.5 Notices. Except as otherwise provided herein, all notices under this
Agreement shall be sent by certified mail or by overnight courier service, postage prepaid, to the following addresses of the respective Parties: 
  

					
	If to Aegerion, to:	 	Aegerion Pharmaceuticals, Inc.
		 	c/o Scheer & Company, Inc.
		 	250 West Main Street
		 	Branford, Connecticut 06405
		 	Attention:	  	President
		
	With a required copy to:	 	Goodwin Procter LLP
		 	53 State Street
		 	Boston, MA 02109
		 	Attention:	  	Kingsley L. Taft, Esq.
		
	If to Bayer, to:	 	Bayer HealthCare AG
		 	Aprather, WEG18A
		 	42096 Wuppertal, Germany
		 	Attention:	  	Dr. Gunnar Riemann, Member of the Board of Management and President of the Pharmaceuticals Division
		
	With a required copy to:	 	Bayer HealthCare
		 	400 Morgan Lane
		 	West haven, CT 06516
		 	Attention:	  	Paul Berry, Senior Vice President, General Counsel and Secretary

or to such address as each Party may hereafter designate by notice to the other Party. A notice shall be deemed to have been given on the date it is
received by all required recipients for the noticed Party. 
 10.6 Dispute Resolution. Disputes arising under or in
connection with this Agreement shall be resolved pursuant to this Section 10.6; provided, however, that in the event a dispute cannot be resolved without an adjudication of the rights or obligations of a Third Party (other than a Bayer
Indemnitee or Aegerion Indemnitee identified in Sections 8.6(a) or 8.6(b), as applicable), the dispute procedures set forth in this Section 10.6 shall be inapplicable as to such dispute. 

(a) In the event of a dispute between the Parties, the Parties shall first attempt in good faith to resolve such dispute
by negotiation and consultation between themselves. In the event that such dispute is not resolved on an informal basis within forty-five (45) days, any Party may, by written notice to the other, have such dispute referred to each of the
Parties’ respective CEOs or his or her designee (who shall be a senior executive), who shall attempt in good faith to resolve such dispute by negotiation and consultation for a thirty (30) day period following receipt of such written
notice. 
 (b) In the event the Parties’ CEOs (or designees) are not able to resolve such dispute, either
Party may at any time after such 30-day period submit such dispute to be finally settled by arbitration administered in accordance with the Commercial Arbitration Rules of the American Arbitration Association (“AAA”) in effect at the time
of submission. The arbitration shall be heard and determined by three (3) arbitrators. Aegerion and Bayer shall each appoint one arbitrator and the third arbitrator shall be selected by the two Party-appointed arbitrators, or, failing agreement
within sixty e(60) days following the date of receipt by the respondent of the claim, by the AAA. Such arbitration shall take place in New York, NY. The arbitration award so given shall be a final and binding determination of the dispute, shall be
fully enforceable in any court of competent jurisdiction, and shall not include any damages expressly prohibited by Section 8.4. 
  

 23 

 LICENSE AGREEMENT 

 

 (c) Costs of arbitration are to be divided by the Parties in the
following manner: Aegerion shall pay for the arbitrator it chooses, Bayer shall pay for the arbitrator it chooses, and the costs of the third arbitrator shall be divided equally between the Parties. Except in a proceeding to enforce the results of
the arbitration or as otherwise required by law, neither Party nor any arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of both Parties. 

10.7 Applicable Law. This Agreement shall be governed by and construed in accordance with the laws of the state of New Jersey,
without regard to its conflicts of law provisions. 
 10.8 Further Assurances. Each Party agrees to do and perform all
such further acts and things and shall execute and deliver such other agreements, certificates, instruments and documents necessary or that the other Party may deem advisable in order to carry out the intent and accomplish the purposes of this
Agreement and to evidence, perfect or otherwise confirm its rights hereunder. 
 10.9 Relationship of the Parties. Each
Party is an independent contractor under this Agreement. Nothing contained herein is intended or is to be construed so as to constitute Bayer and Aegerion as partners, agents or joint venturers. Neither Party shall have any express or implied right
or authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the other Party to any contract, agreement or undertaking with any Third Party. There are no express or implied third party beneficiaries
hereunder (except for Aegerion Indemnitees other than Aegerion and Bayer Indemnitees other than Bayer for purposes of Section 8.6). 

10.10 Entire Agreement. This Agreement (along with the Exhibits) contains the entire understanding of the Parties with respect to
the subject matter hereof and supersedes and replaces any and all previous arrangements and understandings, including the Confidentiality Agreement, whether oral or written, between the Parties with respect to the subject matter hereof. 

10.11 Headings. The captions to the several Sections hereof are not a part of this Agreement, but are merely guides or labels to
assist in locating and reading the several Sections hereof. 
 10.12 Waiver of Rule of Construction. Each Party has had
the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting party shall not
apply. 
 10.13 Interpretation. Whenever any provision of this Agreement uses the term “including” (or
“includes”), such term shall be deemed to mean “including without limitation” (or “includes without limitations”). “Herein,” “hereby,” “hereunder,” “hereof” and other
equivalent words refer to this Agreement as an entirety and not solely to the particular portion of this Agreement in which any such word is used. All definitions set forth herein shall be deemed applicable whether the words defined are used herein
in the singular or the plural. Unless otherwise provided, all references to Sections and Exhibits in this Agreement are to Sections and Exhibits of this Agreement. References to any Sections include Sections and subsections that are part of the
related Section (e.g., a section numbered “Section 2.2” would be part of “Section 2”, and references to “Section 2.2” would also refer to material contained in the subsection described as
“Section 2.2(a)”) 
 10.14 Counterparts; Facsimiles. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. Facsimile execution and delivery of this Agreement by either Party shall constitute a legal, valid and binding execution
and delivery of this Agreement by such Party. 
 [Remainder of this Page Intentionally Left Blank] 

 

 24 

 LICENSE AGREEMENT 

 

 IN WITNESS WHEREOF, the Parties have caused this License Agreement to be executed by
their respective duly authorized officers as of the Effective Date. 
  

			
	BAYER HEALTHCARE AG
		
	By:	 	/s/ Gunnar Riemann
		 	(Signature)
	Name:	 	Dr. Gunnar Riemann
	Title:	 	Member of the Board of Management and President of the Pharmaceuticals Division
		
	Date:	 	June 5, 2006

  

			
	BAYER HEALTHCARE AG
		
	By:	 	/s/ Alexander Bey
		 	(Signature)
	Name:	 	Alexander Bey
	Title:	 	CAO, Head of Law and Patents
		
	Date:	 	May 31, 2006

  

			
	AEGERION PHARMACEUTICALS, INC.
		
	By:	 	/s/ Gerald Wisler
		 	(Signature)
	Name:	 	Gerald Wisler
	Title:	 	President & CEO
		
	Date:	 	May 24, 2006

 LICENSE AGREEMENT 

 

 EXHIBIT A 

BAYER KNOW-HOW TO BE TRANSFERRED TO AEGERION 

 

	 	•	 	 Most recent version of the investigators brochure for implitapide (BAY 13-9952) 

 

	 	•	 	 Complete contents of the implitapide (BAY 13-9952) Investigational New Drug Application filed with the FDA including: 

 

	 	•	 	 In vitro, preclinical and clinical study and trial protocols 

 

	 	•	 	 In vivo, preclinical and clinical study and trial data sets and study reports 

 

	 	•	 	 Chemistry, Manufacturing and Control information 

  

	 	•	 	 Correspondence with FDA 

  

	 	•	 	 Other research and development items not included within those Investigational New Drug Application files including: 

 

	 	•	 	 Publications (meeting abstracts and journal articles) 

 

	 	•	 	 Methods relating to manufacture of implitapide (BAY 13-9952) and drug product formulation 

 

	 	•	 	 Protocols, data sets and study reports relating to preclinical and clinical studies 

 

	 	•	 	 Correspondence and submissions with any other regulatory authorities 

Bayer shall not be required to transfer to Aegerion any Bayer Know-How for which Bayer does not have the right to transfer to Aegerion (including data
owned by PPD). 

 LICENSE AGREEMENT 

EXHIBIT B-1 

BAYER PATENT RIGHTS 

BAYER PATENT RIGHTS UNDER SECTION 1.3(a) 

 

															
	 Le A 30 699

								
	 Land
	  	Anmeldenr.	  	Anmeldedat.	  	Erteilungsnr.	  	Erteilungsdat.	  	Ablaufdat.	  	Veröff.-nr.	  	Offenl.-dat.
	 AR
	  	333677	  	28.09.1995	  		  		  	28.09.2015	  		  	
	 AR 01
	  	104863	  	15.09.2000	  		  		  	28.09.2015	  		  	
	 AU
	  	32920-95	  	27.09.1995	  	700609	  	20.11.1998	  	27.09.2015	  		  	
	 BY
	  	950624	  	03.10.1995	  	5422	  	24.04.2003	  	03.10.2015	  		  	
	 CA
	  	2159546	  	29.09.1995	  		  		  	29.09.2015	  		  	
	 CL
	  	1513-95	  	02.10.1995	  	40031	  	19.07.1999	  	19.07.2014	  		  	
	 CN
	  	95117117	  	04.10.1995	  	52189	  	10.12.1999	  	04.10.2015	  		  	
	 CN 01
	  	98126085	  	30.12.1998	  		  		  	04.10.2015	  		  	
	 CZ
	  	2567-95	  	03.10.1995	  	291348	  	11.12.2002	  	03.10.2015	  		  	
	 DO
	  		  	27.09.1995	  	5232	  	11.04.1996	  	27.09.2010	  		  	
	 DZ
	  	116-95	  	02.10.1995	  		  		  	02.10.2015	  		  	
	 EE
	  	9500071	  	03.10.1995	  	3527	  	15.10.2001	  	03.10.2015	  		  	
	 FI
	  	954681	  	02.10.1995	  	113048	  	27.02.2004	  	02.10.2015	  		  	
	 FI 01
	  	20002693	  	08.12.2000	  	108791	  	28.03.2002	  	02.10.2015	  		  	
	 HK
	  	98104346	  	19.05.1998	  		  		  	20.09.2015	  		  	
	 HN
	  	9160-95	  	29.09.1995	  	3769-181-VII	  	15.06.2000	  	29.09.2015	  		  	
	 HU
	  	9502891	  	03.10.1995	  		  		  	03.10.2015	  		  	
	 ID
	  	952018	  	04.10.1995	  	9015	  	21.10.2002	  	04.10.2015	  		  	
	 IL
	  	115493	  	02.10.1995	  	115493	  	30.01.2000	  	02.10.2015	  		  	
	 IL 01
	  	129641	  	28.04.1999	  	129641	  	03.12.2000	  	02.10.2015	  		  	
	 JP
	  	279664-95	  	04.10.1995	  		  		  	04.10.2015	  		  	
	 KR
	  	33651-95	  	02.10.1995	  	355986	  	26.09.2002	  	02.10.2015	  		  	
	 M1
	  	1323	  	02.10.1995	  		  		  	02.10.2015	  		  	
	 MA
	  	24026	  	02.10.1995	  	23682	  		  	02.10.2015	  		  	
	 MX
	  	954196	  	03.10.1995	  	193845	  	27.10.1999	  	03.10.2015	  		  	
	 MX 01
	  	997137	  	02.08.1999	  		  		  	03.10.2015	  		  	
	 MY
	  	95002964	  	04.10.1995	  		  		  	04.10.2015	  		  	
	 NO
	  	953930	  	03.10.1995	  	305365	  	18.05.1999	  	03.10.2015	  		  	
	 NZ
	  	280130	  	29.09.1995	  	280130	  		  	29.09.2015	  		  	
	 PH
	  	51415	  	03.10.1995	  	31400	  	29.10.1998	  	29.10.2015	  		  	
	 PH 01
	  	1-1998-02241	  	28.08.1998	  		  		  	28.08.2018	  		  	

															
	 Le A 30 699

								
	 Land
	  	Anmeldenr.	  	Anmeldedat.	  	Erteilungsnr.	  	Erteilungsdat.	  	Ablaufdat.	  	Veröff.-nr.	  	Offenl.-dat.
	 PL
	  	310756	  	03.10.1995	  	183154	  	09.10.2001	  	03.10.2015	  		  	
	 RU
	  	95117070	  	03.10.1995	  	2157803	  	20.10.2000	  	03.10.2015	  		  	
	 SG
	  	9501478	  	03.10.1995	  	63528	  	30.03.1999	  	03.10.2015	  		  	
	 SK
	  	1239-95	  	03.10.1995	  		  		  	03.10.2015	  		  	
	 TH
	  	28216	  	02.10.1995	  	13768	  	01.11.2002	  	02.10.2015	  		  	
	 TN
	  	95098	  	02.10.1995	  		  		  	02.10.2015	  		  	
	 TW
	  	84-110247	  	02.10.1995	  	140388	  	04.01.2002	  	01.10.2015	  		  	
	 UA
	  	95104372	  	03.10.1995	  	44700	  	15.03.2002	  	03.10.2015	  		  	
	 US
	  	535698	  	28.09.1995	  	5684014	  	04.11.1997	  	28.09.2015	  		  	
	 US 01
	  	887781	  	03.07.1997	  	6245775	  	12.06.2001	  	28.09.2015	  		  	
	 US 02
	  	313035	  	17.05.1999	  	6265431	  	24.07.2001	  	28.09.2015	  		  	
	 US 03
	  	734955	  	11.12.2000	  		  		  	11.12.2020	  		  	
	 US 04
	  	814263	  	21.03.2001	  	6479503	  	12.11.2002	  	28.09.2015	  		  	
	 US 05
	  	198315	  	18.07.2002	  		  		  		  		  	
	 ZA
	  	95-8297	  	03.10.1995	  	95-8297	  		  	03.10.2015	  		  	
	
	 Le A 30 699

								
	 Land
	  	Anmeldenr.	  	Anmeldedat.	  	Erteilungsnr.	  	Erteilungsdat.	  	Ablaufdat.	  	Veröff.-nr.	  	Offenl.-dat.
	 E BE
	  	95114877.4	  	21.09.1995	  	EBE 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E DE
	  	95114877.4	  	21.09.1995	  	59510839.3	  	03.12.2003	  	21.09.2015	  		  	
	 E DK
	  	95114877.4	  	21.09.1995	  	EDK 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E EP
	  	95114877.4	  	21.09.1995	  	95114877.4	  	03.12.2003	  	21.09.2015	  	705831	  	10.04.1996
	 E ES
	  	95114877.4	  	21.09.1995	  	EES 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E FR
	  	95114877.4	  	21.09.1995	  	EFR 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E GB
	  	95114877.4	  	21.09.1995	  	EGB 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E GR
	  	95114877.4	  	21.09.1995	  	EGR 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E IE
	  	95114877.4	  	21.09.1995	  	EIE 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E IT
	  	95114877.4	  	21.09.1995	  	EIT 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E LT
	  	95114877.4	  	21.09.1995	  	ELT 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E LU
	  	95114877.4	  	21.09.1995	  	ELU 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E LV
	  	95114877.4	  	21.09.1995	  	ELV 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E NL
	  	95114877.4	  	21.09.1995	  	ENL 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E PT
	  	95114877.4	  	21.09.1995	  	EPT 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E SE
	  	95114877.4	  	21.09.1995	  	95114877.4	  	03.12.2003	  	21.09.2015	  		  	

															
	 Le A 34 644

								
	 Land
	  	Anmeldenr.	  	Anmeldedat.	  	Erteilungsnr.	  	Erteilungsdat.	  	Ablaufdat.	  	Veröff.-nr.	  	Offenl.-dat.
	 CA
	  	2413277	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 JP
	  	503264-2002	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 US
	  	311761	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E AT
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E BE
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E CH
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E CY
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E DE
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E DK
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E EP
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  	1296681	  	02.04.2003
	 E ES
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E FI
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E FR
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E GB
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E GR
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E IE
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E IT
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E LU
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E MC
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E NL
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E PT
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E SE
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E TR
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 P WO
	  	PCT/01/06526	  	08.06.2001	  		  		  	08.06.2021	  	01/97787	  	27.12.2001

															
	 Le A 31 659

								
	 Land
	  	Anmeldenr.	  	Anmeldedat.	  	Erteilungsnr.	  	Erteilungsdat.	  	Ablaufdat.	  	Veröff.-nr.	  	Offenl.-dat.
	 CA
	  	2201435	  	01.04.1997	  		  		  	01.04.2017	  		  	
	 JP
	  	96351-97	  	01.04.1997	  		  		  	01.04.2017	  		  	
	 US
	  	829566	  	31.03.1997	  	5952498	  	14.09.1999	  	31.03.2017	  		  	
	 US 01
	  	307980	  	10.05.1999	  		  		  		  		  	
	 E DE
	  	97104941.6	  	24.03.1997	  	59710487.5	  	30.07.2003	  	24.03.2017	  		  	
	 E EP
	  	97104941.6	  	24.03.1997	  	97104941.6	  	30.07.2003	  	24.03.2017	  	799829	  	08.10.1997
	 E ES
	  	97104941.6	  	24.03.1997	  	EES 0799829	  	30.07.2003	  	24.03.2017	  		  	
	 E FR
	  	97104941.6	  	24.03.1997	  	EFR 0799829	  	30.07.2003	  	24.03.2017	  		  	
	 E GB
	  	97104941.6	  	24.03.1997	  	EGB 0799829	  	30.07.2003	  	24.03.2017	  		  	
	 E IT
	  	97104941.6	  	24.03.1997	  	EIT 0799829	  	30.07.2003	  	24.03.2017	  		  	
	 E SE
	  	97104941.6	  	24.03.1997	  	97104941.6	  	30.07.2003	  	24.03.2017	  		  	
	
	 Le A 33 739

								
	 Land
	  	Anmeldenr.	  	Anmeldedat.	  	Erteilungsnr.	  	Erteilungsdat.	  	Ablaufdat.	  	Veröff.-nr.	  	Offenl.-dat.
	 CA
	  	2378379	  	12.07.2000	  		  		  	12.07.2020	  		  	
	 JP
	  	511902-2001	  	12.07.2000	  		  		  		  		  	
	 US
	  	31129	  	12.07.2000	  	6569455	  	27.05.2003	  	12.07.2020	  		  	
	 E DE
	  	00949311.5	  	12.07.2000	  		  		  	12.07.2020	  		  	
	 E EP
	  	00949311.5	  	12.07.2000	  		  		  	12.07.2020	  	1202715	  	08.05.2002
	 E ES
	  	00949311.5	  	12.07.2000	  		  		  	12.07.2020	  		  	
	 E FR
	  	00949311.5	  	12.07.2000	  		  		  	12.07.2020	  		  	
	 E GB
	  	00949311.5	  	12.07.2000	  		  		  	12.07.2020	  		  	
	 E IT
	  	00949311.5	  	12.07.2000	  		  		  	12.07.2020	  		  	
	 P WO
	  	PCT/00/06584	  	12.07.2000	  		  		  	12.07.2020	  	01/07015	  	01.02.2001

 The following patent applications shall also be treated as “Bayer Patent Rights” under this
Agreement, provided that any of the following patent applications may have lapsed, may have been cancelled, or are otherwise no longer still pending as of the Effective Date: 

 

															
	 Le A 30 699

								
	 Land
	  	Anmeldenr.	  	Anmeldedat.	  	Erteilungsnr.	  	Erteilungsdat.	  	Ablaufdat.	  	Veröff.-nr.	  	Offenl.-dat.
	 CU
	  	88-95	  	04.10.1995	  	22885	  	13.03.2003	  	04.10.2010	  		  	
	 HR
	  	950505	  	27.09.1995	  	950505	  	03.04.2002	  	27.09.2015	  		  	
	 MX 01
	  	997137	  	02.08.1999	  		  		  	03.10.2015	  		  	
	 SA
	  	96160624	  	28.02.1996	  		  		  	28.02.2016	  		  	
	 SV
	  	62-95	  	04.10.1995	  	154-1-309	  	11.09.2000	  	04.10.2010	  		  	
	
	 Le A 30 699

								
	 Land
	  	Anmeldenr.	  	Anmeldedat.	  	Erteilungsnr.	  	Erteilungsdat.	  	Ablaufdat.	  	Veröff.-nr.	  	Offenl.-dat.
	 E AT
	  	95114877.4	  	21.09.1995	  	EAT 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E CH
	  	95114877.4	  	21.09.1995	  	ECH 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E MC
	  	95114877.4	  	21.09.1995	  	EMC 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E SI
	  	95114877.4	  	21.09.1995	  	ESI 0705831	  	03.12.2003	  	21.09.2015	  		  	
	
	 Le A 33 846

								
	 Land
	  	Anmeldenr.	  	Anmeldedat.	  	Erteilungsnr.	  	Erteilungsdat.	  	Ablaufdat.	  	Veröff.-nr.	  	Offenl.-dat.
	 AR
	  	103129	  	22.06.2000	  		  		  	22.06.2020	  		  	
	 BS
	  	1242	  	08.06.2000	  	1242	  	29.01.2002	  	08.06.2016	  		  	
	 CA
	  	2376881	  	13.06.2000	  		  		  	13.06.2020	  		  	
	 CL
	  	1671-2000	  	23.06.2000	  		  		  	23.06.2020	  		  	
	 CO
	  	48079	  	27.06.2000	  		  		  	27.06.2020	  		  	
	 DO
	  	04/19/06/00	  	19.06.2000	  		  		  	19.06.2020	  		  	
	 EC
	  	2000-3541	  	23.06.2000	  		  		  	23.06.2020	  		  	
	 GT
	  	2000-0099	  	21.06.2000	  		  		  	21.06.2020	  		  	
	 HN
	  	2000-100	  	15.06.2000	  	4029-431-VII	  	18.10.2001	  	15.06.2020	  		  	
	 JM
	  	18.01.4021	  	16.06.2000	  		  		  	16.06.2014	  		  	
	 JP
	  	505893-2001	  	13.06.2000	  		  		  		  		  	
	 MY
	  	20002807	  	22.06.2000	  		  		  	22.06.2020	  		  	
	 PE
	  	625-2000	  	23.06.2000	  		  		  	23.06.2020	  		  	
	 PH
	  	1-2000-01652	  	23.06.2000	  		  		  	23.06.2020	  		  	
	 PK P
	  	593-2000	  	24.06.2000	  		  		  	24.06.2020	  		  	
	 SV
	  	109-2000	  	23.06.2000	  		  		  	23.06.2020	  		  	

															
	 Le A 30 699

								
	 Land
	  	Anmeldenr.	  	Anmeldedat.	  	Erteilungsnr.	  	Erteilungsdat.	  	Ablaufdat.	  	Veröff.-nr.	  	Offenl.-dat.
	 TH
	  	58386	  	16.06.2000	  		  		  	16.06.2020	  		  	
	 TW
	  	89-112042	  	20.06.2000	  		  		  	20.06.2020	  		  	
	 US
	  	19007	  	13.06.2000	  		  		  		  		  	
	 UY
	  	26218	  	23.06.2000	  		  		  	23.06.2020	  		  	
	 VE
	  	2000-001372	  	22.06.2000	  		  		  	22.06.2020	  		  	
	 E DE
	  	00942056.3	  	13.06.2000	  		  		  	13.06.2020	  		  	
	 E EP
	  	00942056.3	  	13.06.2000	  		  		  	13.06.2020	  	1196194	  	17.04.2002
	 E ES
	  	00942056.3	  	13.06.2000	  		  		  	13.06.2020	  		  	
	 E FR
	  	00942056.3	  	13.06.2000	  		  		  	13.06.2020	  		  	
	 E GB
	  	00942056.3	  	13.06.2000	  		  		  	13.06.2020	  		  	
	 E IT
	  	00942056.3	  	13.06.2000	  		  		  	13.06.2020	  		  	
	 P WO
	  	PCT0/00/05410	  	13.06.2000	  		  		  	13.06.2020	  	01/00183	  	04.01.2001

 LICENSE AGREEMENT 

 

 EXHIBIT B-2 

BAYER PATENT RIGHTS 

BAYER IMPROVEMENT PATENTS UNDER SECTION 1.3(b)

To be updated by the parties as contemplated by Section 6.1 

 LICENSE AGREEMENT 

 

 EXHIBIT C 

SUMMARY OF BATCHES IN BAYER’S INVENTORY OF LICENSED COMPOUND 

[CONFIDENTIAL TREATMENT REQUESTED] /*/ 

 LICENSE AGREEMENT 

 

 EXHIBIT D 

PROPOSED IMPLITAPIDE CLINICAL DEVELOPMENT PROGRAM 

Phase II Trials* 
  

	 	•	 	 Dose-ranging trials to determine the efficacy, safety and tolerability of implitapide monotherapy in patients with primary hypercholesterolemia or
mixed dyslipidemia 

  

	 	•	 	 Dose-ranging trials to determine the efficacy, safety and tolerability of implitapide used in combination with other commonly used lipid-lowering
therapies in patients with primary hypercholesterolemia or mixed dyslipidemia 

  

	*	Note that the number and design of trials conducted in this phase of research will be determined by the scope, completeness and availability of the data related to the
phase II trials conducted by Pharmaceutical Product Development, Inc. 

 Phase III Trials** 

Larger-scale phase 3 trials will be conducted to pursue some combination of the following indications: 

 

	 	•	 	 Implitapide monotherapy for the reduction of plasma lipids in patients with primary hypercholesterolemia and mixed dyslipidemia.

  

	 	•	 	 The combination of implitapide and other lipid-lowering agents for the reduction of plasma lipids in patients with primary hypercholesterolemia and
mixed dyslipidemia. 

  

	 	•	 	 Implitapide as monotherapy or as part of combination therapy with other lipid-lowering agents for the reduction of plasma lipids in patients with
severe and/or hereditary forms of dyslipidemia (e.g. heterozygous familial hypercholesterolemia or Frederickson Type IV hypertriglyceridemia). 

  

	**	Note that the exact number and design of the phase 3 clinical program will be determined based upon the findings within the phase II program and consultation with
regulatory authorities. 

 The contents of this Exhibit C by themselves shall not add to Aegerion’s obligations
under this Agreement. 

 LICENSE AGREEMENT 

 

 EXHIBIT E-1 

PATENTS UNDER SECTION 8.1(f) 

United States Patent No. 6,492,365 
 European
Patent No. EP-B-584446 

 LICENSE AGREEMENT 

 

 EXHIBIT E-2 

BAYER’S EXCEPTIONS UNDER SECTION 8.1(g) 

For avoidance of doubt, it is expressly noted that any results and know how, including the final report and inventions obtained by Former Licensees
Dr. Stein and PPD, are not covered by the Bayer Know-How because such results and know how are confidential and the sole and exclusive property of Medical Research Laboratories International, LLC. 

Dr. Stein still has in his possession clinical supply tablets of implitapide. 

 LICENSE AGREEMENT 

 

 EXHIBIT E-3 

BAYER’S EXCEPTIONS UNDER SECTION 8.1(i) 

Bayer has communicated to Aegerion that Bayer’s development of the Licensed Compounds was discontinued by Bayer on the basis of a negative
risk-benefit assessment of the Licensed Compounds conducted by Bayer under their clinical development program. Aegerion acknowledges Bayer made the judgment not to continue development of the Compounds due to what it perceived under its clinical
development program as unacceptable adverse events for daily dosages of 80 mg and 160 mg per day form compared with the observed cholesterol lowering efficacy. 

 Amendment 

to the License Agreement concluded between Bayer HealthCare AG (“Bayer”) and Aegerion Pharmaceuticals, Inc. (“Aegerion”) on
May 31, 2006 (the “Agreement”) 
  

	 	1.	The following patent rights are herewith added to Exhibit B-1 of the Agreement and shall be regarded as Bayer Patent Rights under Section 1.3(a);

 BHC 061035 

EP 06010232.4, filed on 2006-05-18 
  

	 	2.	All other terms and conditions of the Agreement remain unchanged. 

Date: February 15, 2007 
  

					
	 Bayer HealthCare AG
	  		 	
			
	 /s/ Dr. Dieter Linkenheil
	  		 	 /s/ Dr. Markus Albers

	Dr. Dieter Linkenheil	  		 	Dr. Markus Albers
			
	Date: February 15, 2007	  		 	
			
	 /s/ William H. Lewis
	  		 	
	 William H. Lewis

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00179-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00179-of-00352.parquet"}]]